<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PRIMAXIN IV- imipenem and cilastatin sodium injection, powder, for solution </strong><br>Cardinal Health<br></p></div>
<h1>PRIMAXIN<span class="Sup">®</span> I.V.<br>(IMIPENEM AND CILASTATIN FOR INJECTION)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a2bef00f-25cc-4b97-97ba-299097b3d604"></a><a name="section-1"></a><p></p>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of PRIMAXIN<span class="Sup">®</span> I.V. and other antibacterial drugs, PRIMAXIN I.V. should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
<p><span class="Underline"><span class="Bold"><span class="Emphasis">For Intravenous Injection Only</span></span></span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_1b482ebc-142c-40cb-b023-55e18946a182"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">PRIMAXIN I.V. (Imipenem and Cilastatin for Injection) is a sterile formulation of imipenem (a thienamycin antibiotic) and cilastatin sodium (the inhibitor of the renal dipeptidase, dehydropeptidase l), with sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> added as a buffer. PRIMAXIN I.V. is a potent broad spectrum antibacterial agent for intravenous administration.</p>
<p>Imipenem (N-formimidoylthienamycin monohydrate) is a crystalline derivative of thienamycin, which is produced by <span class="Italics">Streptomyces cattleya</span>. Its chemical name is (5<span class="Italics">R </span>,6<span class="Italics">S</span>)-3-[[2-(formimidoylamino)ethyl]thio]-6-[(<span class="Italics">R</span>)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid monohydrate. It is an off-white, nonhygroscopic crystalline compound with a molecular weight of 317.37. It is sparingly soluble in water and slightly soluble in methanol. Its empirical formula is C<span class="Sub">12</span>H<span class="Sub">17</span>N<span class="Sub">3</span>O<span class="Sub">4</span>S•H<span class="Sub">2</span>O, and its structural formula is:</p>
<div class="Figure"><img alt="chemical structure - imipenem" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7aa0ce90-156c-4583-ae6d-9ed3595960c8&amp;name=ebcb1bef-463a-4503-b847-68d45d0aced6-01.jpg"></div>
<p>Cilastatin sodium is the sodium salt of a derivatized heptenoic acid. Its chemical name is sodium (<span class="Italics">Z </span>)-7[[(<span class="Italics">R </span>)-2-amino-2-carboxyethyl]thio]-2-[(<span class="Italics">S </span>)-2,2-dimethylcyclopropanecarboxamido]-2-heptenoate. It is an off-white to yellowish-white, hygroscopic, amorphous compound with a molecular weight of 380.43. It is very soluble in water and in methanol. Its empirical formula is C<span class="Sub">16</span>H<span class="Sub">25</span>N<span class="Sub">2</span>O<span class="Sub">5</span>SNa, and its structural formula is:</p>
<div class="Figure"><img alt="chemical structure - cilastatin sodium" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7aa0ce90-156c-4583-ae6d-9ed3595960c8&amp;name=ebcb1bef-463a-4503-b847-68d45d0aced6-02.jpg"></div>
<p>PRIMAXIN I.V. is buffered to provide solutions in the pH range of 6.5 to 8.5. There is no significant change in pH when solutions are prepared and used as directed. (See <a href="#i4i_section_id_fdfde20b-980f-4ddc-9dee-f792773c4c40">COMPATIBILITY AND STABILITY</a>.) PRIMAXIN I.V. 250 contains 18.8 mg of sodium (0.8 mEq) and PRIMAXIN I.V. 500 contains 37.5 mg of sodium (1.6 mEq). Solutions of PRIMAXIN I.V. range from colorless to yellow. Variations of color within this range do not affect the potency of the product.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_45e74182-a071-4ce4-aaac-d67147200207"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3ea1cf26-71b0-47e5-9c5d-cc4eb4c06b76"></a><a name="section-3.1"></a><p></p>
<h2>Adults</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_eb62fe97-44d1-47b9-8d39-96084fa5b991"></a><a name="section-3.1.1"></a><p></p>
<h3>Intravenous Administration</h3>
<p class="First">Intravenous infusion of PRIMAXIN I.V. over 20 minutes results in peak plasma levels of imipenem antimicrobial activity that range from 14 to 24 µg/mL for the 250 mg dose, from 21 to 58 µg/mL for the 500 mg dose, and from 41 to 83 µg/mL for the 1000 mg dose. At these doses, plasma levels of imipenem antimicrobial activity decline to below 1 µg/mL or less in 4 to 6 hours. Peak plasma levels of cilastatin following a 20-minute intravenous infusion of PRIMAXIN I.V. range from 15 to 25 µg/mL for the 250 mg dose, from 31 to 49 µg/mL for the 500 mg dose, and from 56 to 88 µg/mL for the 1000 mg dose.</p>
<p>The plasma half-life of each component is approximately 1 hour. The binding of imipenem to human serum proteins is approximately 20% and that of cilastatin is approximately 40%. Approximately 70% of the administered imipenem is recovered in the urine within 10 hours after which no further urinary excretion is detectable. Urine concentrations of imipenem in excess of 10 µg/mL can be maintained for up to 8 hours with PRIMAXIN I.V. at the 500‑mg dose. Approximately 70% of the cilastatin sodium dose is recovered in the urine within 10 hours of administration of PRIMAXIN I.V.</p>
<p>No accumulation of imipenem/cilastatin in plasma or urine is observed with regimens administered as frequently as every 6 hours in patients with normal renal function.</p>
<p>In healthy elderly volunteers (65 to 75 years of age with normal renal function for their age), the pharmacokinetics of a single dose of imipenem 500 mg and cilastatin 500 mg administered intravenously over 20 minutes are consistent with those expected in subjects with slight <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> for which no dosage alteration is considered necessary. The mean plasma half-lives of imipenem and cilastatin are 91 ± 7.0 minutes and 69 ± 15 minutes, respectively. Multiple dosing has no effect on the pharmacokinetics of either imipenem or cilastatin, and no accumulation of imipenem/cilastatin is observed.</p>
<p>Imipenem, when administered alone, is metabolized in the kidneys by dehydropeptidase I resulting in relatively low levels in urine. Cilastatin sodium, an inhibitor of this enzyme, effectively prevents renal metabolism of imipenem so that when imipenem and cilastatin sodium are given concomitantly, fully adequate antibacterial levels of imipenem are achieved in the urine.</p>
<p>After a 1 gram dose of PRIMAXIN I.V., the following average levels of imipenem were measured (usually at 1 hour post dose except where indicated) in the tissues and fluids listed:</p>
<a name="id_48530768-69cb-4a62-9109-8e959d1bf12e"></a><table>
<col align="left" width="23%">
<col align="center" width="19%">
<col align="left" width="40%">
<col align="center" width="18%">
<thead><tr class="First Last">
<td class="Botrule" align="left" valign="bottom">Tissue or Fluid</td>
<td class="Botrule" align="center" valign="top">
<br>N</td>
<td class="Botrule" align="center" valign="top">Imipenem Level<br>µg/mL or µg/g</td>
<td class="Botrule" align="center" valign="top">
<br>Range</td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Toprule" align="center" valign="bottom"></td>
<td class="Toprule" align="center" valign="top"></td>
<td class="Toprule" align="left" valign="bottom"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Vitreous Humor</td>
<td align="center" valign="top">3</td>
<td align="left" valign="top">3.4 (3.5 hours post dose)</td>
<td align="center" valign="top">2.88–3.6</td>
</tr>
<tr>
<td align="left" valign="top">Aqueous Humor</td>
<td align="center" valign="top">5</td>
<td align="left" valign="top">2.99 (2 hours post dose)</td>
<td align="center" valign="top">2.4–3.9</td>
</tr>
<tr>
<td align="left" valign="top">Lung Tissue</td>
<td align="center" valign="top">8</td>
<td align="left" valign="top">5.6 (median)</td>
<td align="center" valign="top">3.5–15.5</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">Sputum</span></td>
<td align="center" valign="top">1</td>
<td align="left" valign="top">2.1</td>
<td align="center" valign="top">—</td>
</tr>
<tr>
<td align="left" valign="top">Pleural</td>
<td align="center" valign="top">1</td>
<td align="left" valign="top">22.0</td>
<td align="center" valign="top">—</td>
</tr>
<tr>
<td align="left" valign="top">Peritoneal</td>
<td align="center" valign="top">12</td>
<td align="left" valign="top">23.9 S.D.±5.3 (2 hours post dose)</td>
<td align="center" valign="top">—</td>
</tr>
<tr>
<td align="left" valign="top">Bile</td>
<td align="center" valign="top">2</td>
<td align="left" valign="top">5.3 (2.25 hours post dose)</td>
<td align="center" valign="top">4.6–6.0</td>
</tr>
<tr>
<td align="left" valign="top">CSF (uninflamed)</td>
<td align="center" valign="top">5</td>
<td align="left" valign="top">1.0 (4 hours post dose)</td>
<td align="center" valign="top">0.26–2.0</td>
</tr>
<tr>
<td align="left" valign="top">CSF (inflamed)</td>
<td align="center" valign="top">7</td>
<td align="left" valign="top">2.6 (2 hours post dose)</td>
<td align="center" valign="top">0.5–5.5</td>
</tr>
<tr>
<td align="left" valign="top">Fallopian Tubes</td>
<td align="center" valign="top">1</td>
<td align="left" valign="top">13.6</td>
<td align="center" valign="top">—</td>
</tr>
<tr>
<td align="left" valign="top">Endometrium</td>
<td align="center" valign="top">1</td>
<td align="left" valign="top">11.1</td>
<td align="center" valign="top">—</td>
</tr>
<tr>
<td align="left" valign="top">Myometrium</td>
<td align="center" valign="top">1</td>
<td align="left" valign="top">5.0</td>
<td align="center" valign="top">—</td>
</tr>
<tr>
<td align="left" valign="top">Bone</td>
<td align="center" valign="top">10</td>
<td align="left" valign="top">2.6</td>
<td align="center" valign="top">0.4–5.4</td>
</tr>
<tr>
<td align="left" valign="top">Interstitial Fluid</td>
<td align="center" valign="top">12</td>
<td align="left" valign="top">16.4</td>
<td align="center" valign="top">10.0–22.6</td>
</tr>
<tr>
<td align="left" valign="top">Skin</td>
<td align="center" valign="top">12</td>
<td align="left" valign="top">4.4</td>
<td align="center" valign="top">NA</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">Fascia</td>
<td class="Botrule" align="center" valign="top">12</td>
<td class="Botrule" align="left" valign="top">4.4</td>
<td class="Botrule" align="center" valign="top">NA</td>
</tr>
</tbody>
</table>
<p>Imipenem-cilastatin sodium is hemodialyzable. However, usefulness of this procedure in the overdosage setting is questionable. (See <a href="#i4i_overdosage_id_81188eee-d0e3-498f-8417-e70ee4ee0b4a">OVERDOSAGE</a>.)</p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="i4i_microbiology_id_09e87048-e814-4d13-86d1-823de0959049"></a><a name="section-3.1.2"></a><p></p>
<h3>Microbiology</h3>
<p class="First">The bactericidal activity of imipenem results from the inhibition of cell wall synthesis. Its greatest affinity is for penicillin binding proteins (PBPs) 1A, 1B, 2, 4, 5 and 6 of <span class="Italics">Escherichia coli</span>, and 1A, 1B, 2, 4 and 5 of <span class="Italics">Pseudomonas aeruginosa</span>. The lethal effect is related to binding to PBP 2 and PBP 1B.</p>
<p>Imipenem has a high degree of stability in the presence of beta-lactamases, both penicillinases and cephalosporinases produced by gram-negative and gram-positive bacteria. It is a potent inhibitor of beta-lactamases from certain gram-negative bacteria which are inherently resistant to most beta-lactam antibiotics, e.g., <span class="Italics">Pseudomonas aeruginosa</span>, <span class="Italics">Serratia</span> spp., and <span class="Italics">Enterobacter</span> spp.</p>
<p>Imipenem has <span class="Italics">in vitro</span> activity against a wide range of gram-positive and gram-negative organisms. Imipenem has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms, both <span class="Italics">in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> treated with the intravenous formulation of imipenem-cilastatin sodium as described in the <a href="#i4i_indications_id_03d51ed0-3a56-4c28-9834-ceba5ba21264">INDICATIONS AND USAGE</a> section.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_955fa893-0a7b-4878-9e57-5326075d4ac1"></a><a name="section-3.1.2.1"></a><p></p>
<h4>Gram-positive aerobes:</h4>
<p class="First"><span class="Italics">Enterococcus faecalis </span>(formerly<span class="Italics">S. faecalis</span>)<br>     (NOTE: Imipenem is inactive <span class="Italics">in vitro</span> against <span class="Italics">Enterococcus faecium</span> [formerly<br>     <span class="Italics">S. faecium </span>].)<br><span class="Italics">Staphylococcus aureus</span> including penicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span><br><span class="Italics">Staphylococcus epidermidis</span> including penicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span><br>     (NOTE: Methicillin-resistant staphylococci should be reported as resistant to<br>     imipenem.)<br><span class="Italics">Streptococcus agalactiae</span> (Group B streptococci)<br><span class="Italics">Streptococcus pneumoniae</span><br><span class="Italics">Streptococcus pyogenes</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_445e858f-a65c-4834-94f1-707dadd3d72e"></a><a name="section-3.1.2.2"></a><p></p>
<h4>Gram-negative aerobes:</h4>
<p class="First"><span class="Italics">Acinetobacter</span> spp.<br><span class="Italics">Citrobacter</span> spp.<br><span class="Italics">Enterobacter</span> spp.<br><span class="Italics">Escherichia coli</span><br><span class="Italics">Gardnerella vaginalis</span><br><span class="Italics">Haemophilus influenzae</span><br><span class="Italics">Haemophilus parainfluenzae</span><br><span class="Italics">Klebsiella</span> spp.<br><span class="Italics">Morganella morganii</span><br><span class="Italics">Proteus vulgaris</span><br><span class="Italics">Providencia rettgeri</span><br><span class="Italics">Pseudomonas aeruginosa</span><br>     (NOTE: Imipenem is inactive <span class="Italics">in vitro </span> against <span class="Italics">Stenotrophomonas</span> [formerly <span class="Italics">Xanthomonas</span>, formerly <span class="Italics">Pseudomonas</span>] <span class="Italics">maltophilia</span> and some <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Burkholderia cepacia</span>.)<br><span class="Italics">Serratia</span> spp., including <span class="Italics">S. marcescens</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c47f3fac-72f6-413e-a75c-20bccadc91a4"></a><a name="section-3.1.2.3"></a><p></p>
<h4>Gram-positive anaerobes:</h4>
<p class="First"><span class="Italics">Bifidobacterium</span> spp.<br><span class="Italics">Clostridium</span> spp.<br><span class="Italics">Eubacterium</span> spp.<br><span class="Italics">Peptococcus</span> spp.<br><span class="Italics">Peptostreptococcus</span> spp.<br><span class="Italics">Propionibacterium</span> spp.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_67fd5544-24cb-4ba4-879a-bd15d850acf4"></a><a name="section-3.1.2.4"></a><p></p>
<h4>Gram-negative anaerobes:</h4>
<p class="First"><span class="Italics">Bacteroides</span> spp., including <span class="Italics">B. fragilis</span><br><span class="Italics">Fusobacterium</span> spp.</p>
<p>The following <span class="Italics">in vitro</span> data are available, <span class="Underline"><span class="Bold"><span class="Emphasis">but their clinical significance is unknown</span></span></span>.</p>
<p>Imipenem exhibits <span class="Italics">in vitro</span> <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs) of 4 µg/mL or less against most (≥90%) <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms; however, the safety and effectiveness of imipenem in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these microorganisms have not been established in adequate and well-controlled clinical trials.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f3d81e73-f48e-420f-b8ae-4c8de63aba2e"></a><a name="section-3.1.2.5"></a><p></p>
<h4>Gram-positive aerobes:</h4>
<p class="First"><span class="Italics">Bacillus</span> spp.<br><span class="Italics">Listeria monocytogenes</span><br><span class="Italics">Nocardia</span> spp.<br><span class="Italics">Staphylococcus saprophyticus</span><br>Group C streptococci<br>Group G streptococci<br>Viridans group streptococci</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_65ed5e3b-241d-4feb-99a9-2a0ff58e251d"></a><a name="section-3.1.2.6"></a><p></p>
<h4>Gram-negative aerobes:</h4>
<p class="First"><span class="Italics">Aeromonas hydrophila</span><br><span class="Italics">Alcaligenes</span> spp.<br><span class="Italics">Capnocytophaga</span> spp.<br><span class="Italics">Haemophilus ducreyi</span><br><span class="Italics">Neisseria gonorrhoeae</span> including penicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span><br><span class="Italics">Pasteurella</span> spp.<br><span class="Italics">Providencia stuartii</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fc6940a5-8330-4d8b-b01d-f7db4ae911be"></a><a name="section-3.1.2.7"></a><p></p>
<h4>Gram-negative anaerobes:</h4>
<p class="First"><span class="Italics">Prevotella bivia</span><br><span class="Italics">Prevotella disiens</span><br><span class="Italics">Prevotella melaninogenica</span><br><span class="Italics">Veillonella </span> spp.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_95bf1b4a-6a31-42f7-8dca-233adc710e2a"></a><a name="section-3.1.2.8"></a><p></p>
<p class="First"><span class="Italics">In vitro</span> tests show imipenem to act synergistically with aminoglycoside antibiotics against some isolates of <span class="Italics">Pseudomonas aeruginosa</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3cd007bb-85bb-4456-b190-b6b37e196041"></a><a name="section-3.1.2.9"></a><p></p>
<h4>Susceptibility Test Methods</h4>
<p class="First">When available, the clinical microbiology laboratory should provide to the physician the results of <span class="Italics">in vitro</span> susceptibility tests for antimicrobial drug products used in resident hospitals as periodic reports which describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting the most effective antimicrobial.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_adc4b5e0-fe5a-48c0-a963-e13afc640fee"></a><a name="section-3.1.2.10"></a><p></p>
<h4><span class="Underline">Dilution Techniques</span></h4>
<p class="First">Quantitative methods are used to determine antimicrobial <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on a broth dilution method{1,2} or equivalent with standardized inoculum concentrations and standardized concentrations of imipenem powder. The MIC values should be interpreted according to criteria provided in <a href="#table1">Table 1</a>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_11fd170b-50b1-4aac-b22d-821ac5f32203"></a><a name="section-3.1.2.11"></a><p></p>
<h4><span class="Underline">Diffusion Techniques</span></h4>
<p class="First">Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure requires the use of standardized inoculum concentrations {2,3}. This procedure uses paper disks impregnated with 10-µg imipenem to test the susceptibility of microorganisms to imipenem. The disk diffusion interpretive criteria should be interpreted according to criteria provided in <a href="#table1">Table 1</a>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1865b3d9-e316-4cf7-9be8-b107aa51e1d4"></a><a name="section-3.1.2.12"></a><p></p>
<h4><span class="Underline">Anaerobic Techniques</span></h4>
<p class="First">For anaerobic bacteria, the susceptibility to imipenem as MICs can be determined by standardized test methods.{2,4} The MIC values obtained should be interpreted according to criteria provided in <a href="#table1">Table 1</a>.</p>
<p>The MIC and disk diffusion values obtained should be interpreted according to the following criteria:</p>
<a name="table1"></a><table>
<caption><span>Table 1: Susceptibility Interpretive Criteria for Imipenem</span></caption>
<col align="left" width="34%">
<col align="center" width="11%">
<col align="center" width="11%">
<col align="center" width="11%">
<col align="center" width="11%">
<col align="center" width="11%">
<col align="center" width="11%">
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>For oxacillin-susceptible <span class="Italics">S. aureus</span> and coagulase negative staphylococci results for carbapenems, including imipenem, if tested, should be reported according to the results generated using routine interpretive criteria. For oxacillin-resistant <span class="Italics">S. aureus</span> and coagulase negative staphylococci, other beta lactam agents, including carbapenems, may appear active <span class="Italics">in vitro</span> but are not effective clinically. Results for beta lactam agents other than cephalosporins with anti-MRSA activity should be reported as resistant or should not be reported.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>For some organism/antimicrobial combinations, the absence or rare occurrence of resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> precludes defining any results categories other than "susceptible". For <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> yielding results suggestive of a "non-susceptible" category, organism identification and antimicrobial susceptibility test results should be confirmed.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>For non-<span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> <span class="Italics">S. pneumoniae</span> isolates, penicillin MICs ≤0.06 µg/mL (or oxacillin zones ≥20 mm) indicate susceptibility to imipenem. </dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First Toprule">
<td align="left" valign="top">Pathogen</td>
<td class="Toprule" align="center" colspan="3" valign="top"><span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">Minimum Inhibitory Concentrations</span><br>MIC (µg/mL)</td>
<td align="center" colspan="3" valign="top">Disk Diffusion<br>Zone Diameter (mm)</td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="left" valign="top">S</td>
<td align="left" valign="top">I</td>
<td align="left" valign="top">R</td>
<td align="left" valign="top">S</td>
<td align="left" valign="top">I</td>
<td align="left" valign="top">R</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Italics">Enterobacteriaceae</span></td>
<td align="left" valign="top">≤1.0</td>
<td align="left" valign="top">2.0</td>
<td align="left" valign="top">≥4.0</td>
<td align="left" valign="top">≥23</td>
<td align="left" valign="top">20-22</td>
<td align="left" valign="top">≤19</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Italics">Pseudomonas aeruginosa</span></td>
<td align="left" valign="top">≤2</td>
<td align="left" valign="top">4</td>
<td align="left" valign="top">≥8</td>
<td align="left" valign="top">≥19</td>
<td align="left" valign="top">16-18</td>
<td align="left" valign="top">≤15</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Italics">Acinetobacter </span>spp.</td>
<td align="left" valign="top">≤4</td>
<td align="left" valign="top">8</td>
<td align="left" valign="top">≥16</td>
<td align="left" valign="top">≥16</td>
<td align="left" valign="top">14-15</td>
<td align="left" valign="top">≤13</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Italics">Staphylococcus </span>spp.<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</td>
<td align="left" valign="top">≤4</td>
<td align="left" valign="top">8</td>
<td align="left" valign="top">≥16</td>
<td align="left" valign="top">≥16</td>
<td align="left" valign="top">14-15</td>
<td align="left" valign="top">≤13</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Italics">Haemophilus influenzae </span>and <span class="Italics">H. parainfluenzae</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</td>
<td align="left" valign="top">≤4</td>
<td align="left" valign="top">-</td>
<td align="left" valign="top">-</td>
<td align="left" valign="top">≥16</td>
<td align="left" valign="top">-</td>
<td align="left" valign="top">-</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Italics">Streptococcus pneumoniae</span><a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a>
</td>
<td align="left" valign="top">≤0.12</td>
<td align="left" valign="top">0.25-0.5</td>
<td align="left" valign="top">≥1</td>
<td align="left" valign="top">-</td>
<td align="left" valign="top">-</td>
<td align="left" valign="top">-</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top">Anaerobes</td>
<td align="left" valign="top">≤4.0</td>
<td align="left" valign="top">8.0</td>
<td align="left" valign="top">≥16.0</td>
<td align="left" valign="top">-</td>
<td align="left" valign="top">-</td>
<td align="left" valign="top">-</td>
</tr>
</tbody>
</table>
<p>A report of "Susceptible" indicates that the pathogen is likely to be inhibited if the antimicrobial compound at the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> site reaches the concentrations usually achievable. A report of "Intermediate" indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of "Resistant" indicates that the pathogen is not likely to be inhibited if the antimicrobial compound at the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> site reaches the concentrations usually achievable, and that other therapy should be selected.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f68748e8-22d7-4a72-93f1-94fde39cbb0c"></a><a name="section-3.1.2.13"></a><p></p>
<h4><span class="Underline">Quality Control</span></h4>
<p class="First">Standardized susceptibility test procedures require the use of laboratory control microorganisms to ensure the accuracy and precision of supplies and reagents used in the assay, and the techniques of the individuals performing the test. Quality control microorganisms are specific <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of organisms with intrinsic biological properties. QC <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> are very stable <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> which will give a standard and repeatable susceptibility pattern. The specific <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> used for microbiological quality control are not clinically significant. Standard imipenem powder should provide the following range of values noted in <a href="#table2">Table 2</a>.{2}</p>
<a name="table2"></a><table>
<caption><span>Table 2: Acceptable Quality Control Ranges for Imipenem</span></caption>
<col align="left" width="40%">
<col align="center" width="40%">
<col align="center" width="20%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>Quality control ranges for broth microdilution testing</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">†</a></dt>
<dd>Quality control ranges for agar dilution testing</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First Toprule">
<td align="left" valign="top">Microorganism</td>
<td class="Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">Minimum Inhibitory Concentrations</span><br>MIC Range (µg/mL)</td>
<td align="left" valign="top">Disk Diffusion<br>Zone Diameter (mm)</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Italics">Pseudomonas aeruginosa </span>ATCC 27853</td>
<td align="left" valign="top">1-4</td>
<td align="left" valign="top">20-28</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Italics">Escherichia coli </span>ATCC 25922</td>
<td align="left" valign="top">0.06-0.25</td>
<td align="left" valign="top">26-32</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Italics">Haemophilus influenzae </span>ATCC 49247</td>
<td align="left" valign="top">-</td>
<td align="left" valign="top">21-29</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Italics">Haemophilus influenzae </span>ATCC 49766</td>
<td align="left" valign="top">0.25-1.0</td>
<td align="left" valign="top">-</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Italics">Staphylococcus aureus </span>ATCC 29213</td>
<td align="left" valign="top">0.015-0.06</td>
<td align="left" valign="top">-</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Italics">Enterococcus faecalis </span>ATCC 29212</td>
<td align="left" valign="top">0.5-2.0</td>
<td align="left" valign="top">-</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Italics">Streptococcus pneumoniae </span>ATCC 49619</td>
<td align="left" valign="top">0.03-0.12</td>
<td align="left" valign="top">-</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Italics">Bacteroides fragilis </span>ATCC 25285</td>
<td align="left" valign="top">0.03-0.25<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a><br>0.03-0.125<a name="footnote-reference-5" href="#footnote-5" class="Sup">†</a>
</td>
<td align="left" valign="top">-</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Italics">Bacteroides thetaiotaomicron </span>ATCC 29741</td>
<td align="left" valign="top">0.25-1.0<a href="#footnote-4" class="Sup">*</a><br>0.125-0.5<a href="#footnote-5" class="Sup">†</a>
</td>
<td align="left" valign="top">-</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top">
<span class="Italics">Eubacterium lentum </span>ATCC 43055</td>
<td align="left" valign="top">0.25-2.0<a href="#footnote-4" class="Sup">*</a><br>0.125-0.5<a href="#footnote-5" class="Sup">†</a>
</td>
<td align="left" valign="top">-</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_03d51ed0-3a56-4c28-9834-ceba5ba21264"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">PRIMAXIN I.V. is indicated for the treatment of serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the designated microorganisms in the conditions listed below:</p>
<ol>
<li>
<span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">Lower respiratory tract infections</span></span></span>. <span class="Italics">Staphylococcus aureus</span> (penicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), <span class="Italics">Acinetobacter</span> species, <span class="Italics">Enterobacter</span> species, <span class="Italics">Escherichia coli</span>, <span class="Italics">Haemophilus influenzae</span>, <span class="Italics">Haemophilus parainfluenzae</span><a name="footnote-reference-6" href="#footnote-6" class="Sup">1</a>, <span class="Italics">Klebsiella </span> species, <span class="Italics">Serratia marcescens</span>
</li>
<li>
<span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infections</span></span></span> (complicated and uncomplicated). <span class="Italics">Enterococcus faecalis</span>, <span class="Italics">Staphylococcus aureus</span> (penicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)<a name="footnote-reference-7" href="#footnote-7" class="Sup">2</a>, <span class="Italics">Enterobacter</span> species, <span class="Italics">Escherichia coli</span>, <span class="Italics">Klebsiella</span> species, <span class="Italics">Morganella morganii</span><a name="footnote-reference-8" href="#footnote-8" class="Sup">3</a>, <span class="Italics">Proteus vulgaris</span><a name="footnote-reference-9" href="#footnote-9" class="Sup">4</a>, <span class="Italics">Providencia rettgeri</span><a name="footnote-reference-10" href="#footnote-10" class="Sup">5</a>, <span class="Italics">Pseudomonas aeruginosa</span>
</li>
<li>
<span class="Bold"><span class="Emphasis">Intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">abdominal infections</span></span></span>. <span class="Italics">Enterococcus faecalis</span>, <span class="Italics">Staphylococcus aureus</span> (penicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)<a name="footnote-reference-11" href="#footnote-11" class="Sup">6</a>, <span class="Italics">Staphylococcus epidermidis</span>, <span class="Italics">Citrobacter</span> species, <span class="Italics">Enterobacter</span> species, <span class="Italics">Escherichia coli</span>, <span class="Italics">Klebsiella</span> species, <span class="Italics">Morganella morganii</span><a name="footnote-reference-12" href="#footnote-12" class="Sup">7</a>, <span class="Italics">Proteus</span> species, <span class="Italics">Pseudomonas aeruginosa</span>, <span class="Italics">Bifidobacterium </span> species, <span class="Italics">Clostridium </span> species, <span class="Italics">Eubacterium</span> species, <span class="Italics">Peptococcus </span> species, <span class="Italics">Peptostreptococcus </span> species, <span class="Italics">Propionibacterium</span> species<a name="footnote-reference-13" href="#footnote-13" class="Sup">8</a>, <span class="Italics">Bacteroides</span> species including <span class="Italics">B. fragilis</span>, <span class="Italics">Fusobacterium </span> species</li>
<li>
<span class="Bold"><span class="Emphasis">Gynecologic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. </span></span><span class="Italics">Enterococcus faecalis</span>, <span class="Italics">Staphylococcus aureus</span> (penicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)<a name="footnote-reference-14" href="#footnote-14" class="Sup">9</a>, <span class="Italics">Staphylococcus epidermidis</span>, <span class="Italics">Streptococcus agalactiae</span> (Group B streptococci), <span class="Italics">Enterobacter</span> species<a name="footnote-reference-15" href="#footnote-15" class="Sup">10</a>, <span class="Italics">Escherichia coli</span>, <span class="Italics">Gardnerella vaginalis</span>, <span class="Italics">Klebsiella</span> species<a name="footnote-reference-16" href="#footnote-16" class="Sup">11</a>, <span class="Italics">Proteus</span> species, <span class="Italics">Bifidobacterium</span> species<a name="footnote-reference-17" href="#footnote-17" class="Sup">12</a>, <span class="Italics">Peptococcus</span> species<a name="footnote-reference-18" href="#footnote-18" class="Sup">13</a>, <span class="Italics">Peptostreptococcus</span> species, <span class="Italics">Propionibacterium</span> species<a name="footnote-reference-19" href="#footnote-19" class="Sup">14</a>, <span class="Italics">Bacteroides</span> species including <span class="Italics">B. fragilis</span><a name="footnote-reference-20" href="#footnote-20" class="Sup">15</a>
</li>
<li>
<span class="Bold"><span class="Emphasis">Bacterial <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span>. </span></span><span class="Italics">Enterococcus faecalis</span>, <span class="Italics">Staphylococcus aureus</span> (penicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), <span class="Italics">Enterobacter</span> species, <span class="Italics">Escherichia coli</span>, <span class="Italics">Klebsiella</span> species, <span class="Italics">Pseudomonas aeruginosa</span>, <span class="Italics">Serratia</span> species<a name="footnote-reference-21" href="#footnote-21" class="Sup">16</a>, <span class="Italics">Bacteroides</span> species including <span class="Italics">B. fragilis</span><a name="footnote-reference-22" href="#footnote-22" class="Sup">17</a>
</li>
<li>
<span class="Bold"><span class="Emphasis">Bone and <span class="product-label-link" type="condition" conceptid="4180167" conceptname="Infectious disorder of joint">joint infections</span>. </span></span><span class="Italics">Enterococcus faecalis</span>, <span class="Italics">Staphylococcus aureus</span> (penicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), <span class="Italics">Staphylococcus epidermidis</span>, <span class="Italics">Enterobacter</span> species, <span class="Italics">Pseudomonas aeruginosa</span>
</li>
<li>
<span class="Bold"><span class="Emphasis">Skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. </span></span><span class="Italics">Enterococcus faecalis</span>, <span class="Italics">Staphylococcus aureus</span> (penicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), <span class="Italics">Staphylococcus epidermidis</span>, <span class="Italics">Acinetobacter</span> species, <span class="Italics">Citrobacter</span> species, <span class="Italics">Enterobacter</span> species, <span class="Italics">Escherichia coli</span>, <span class="Italics">Klebsiella</span> species, <span class="Italics">Morganella morganii</span>, <span class="Italics">Proteus vulgaris</span>, <span class="Italics">Providencia rettgeri</span><a name="footnote-reference-23" href="#footnote-23" class="Sup">18</a>, <span class="Italics">Pseudomonas aeruginosa</span>, <span class="Italics">Serratia</span> species, <span class="Italics">Peptococcus</span> species, <span class="Italics">Peptostreptococcus</span> species, <span class="Italics">Bacteroides</span> species including <span class="Italics">B. fragilis</span>, <span class="Italics">Fusobacterium</span> species<a name="footnote-reference-24" href="#footnote-24" class="Sup">19</a>
</li>
<li>
<span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">Endocarditis</span></span></span>. <span class="Italics">Staphylococcus aureus</span> (penicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)</li>
<li>
<span class="Bold"><span class="Emphasis">Polymicrobic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></span></span>. PRIMAXIN I.V. is indicated for polymicrobic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> including those in which <span class="Italics">S. pneumoniae</span> (<span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span>), <span class="Italics">S. pyogenes </span> (skin and skin structure), or nonpenicillinase-producing <span class="Italics">S. aureus</span> is one of the causative organisms. However, monobacterial <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these organisms are usually treated with narrower spectrum antibiotics, such as penicillin G.</li>
</ol>
<p>PRIMAXIN I.V. is not indicated in patients with <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> because safety and efficacy have not been established.</p>
<p>For Pediatric Use information, see <a href="#i4i_pediatric_use_id_49de5c25-49ec-4f5d-b1c3-d1d61c68c8fe">PRECAUTIONS, Pediatric Use</a>, and <a href="#i4i_dosage_admin_id_f8c49d4e-a947-4717-a237-be0dafc4f4d6">DOSAGE AND ADMINISTRATION</a> sections.</p>
<p>Because of its broad spectrum of bactericidal activity against gram-positive and gram-negative aerobic and anaerobic bacteria, PRIMAXIN I.V. is useful for the treatment of mixed <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and as presumptive therapy prior to the identification of the causative organisms.</p>
<p>Although clinical improvement has been observed in patients with <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span>, chronic pulmonary disease, and <span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">lower respiratory tract infections</span> caused by <span class="Italics">Pseudomonas aeruginosa</span>, bacterial eradication may not necessarily be achieved.</p>
<p>As with other beta-lactam antibiotics, some <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Pseudomonas aeruginosa</span> may develop resistance fairly rapidly during treatment with PRIMAXIN I.V. During therapy of <span class="Italics">Pseudomonas aeruginosa</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, periodic susceptibility testing should be done when clinically appropriate.</p>
<p><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> resistant to other antibiotics, for example, cephalosporins, penicillin, and aminoglycosides, have been shown to respond to treatment with PRIMAXIN I.V.</p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of PRIMAXIN I.V. and other antibacterial drugs, PRIMAXIN I.V. should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">1</a></dt>
<dd><p class="First">Efficacy for this organism in this organ system was studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p></dd>
<dt><a name="footnote-7" href="#footnote-reference-7">2</a></dt>
<dd><p class="First">Efficacy for this organism in this organ system was studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p></dd>
<dt><a name="footnote-8" href="#footnote-reference-8">3</a></dt>
<dd><p class="First">Efficacy for this organism in this organ system was studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p></dd>
<dt><a name="footnote-9" href="#footnote-reference-9">4</a></dt>
<dd><p class="First">Efficacy for this organism in this organ system was studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p></dd>
<dt><a name="footnote-10" href="#footnote-reference-10">5</a></dt>
<dd><p class="First">Efficacy for this organism in this organ system was studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p></dd>
<dt><a name="footnote-11" href="#footnote-reference-11">6</a></dt>
<dd><p class="First">Efficacy for this organism in this organ system was studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p></dd>
<dt><a name="footnote-12" href="#footnote-reference-12">7</a></dt>
<dd><p class="First">Efficacy for this organism in this organ system was studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p></dd>
<dt><a name="footnote-13" href="#footnote-reference-13">8</a></dt>
<dd><p class="First">Efficacy for this organism in this organ system was studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p></dd>
<dt><a name="footnote-14" href="#footnote-reference-14">9</a></dt>
<dd><p class="First">Efficacy for this organism in this organ system was studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p></dd>
<dt><a name="footnote-15" href="#footnote-reference-15">10</a></dt>
<dd><p class="First">Efficacy for this organism in this organ system was studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p></dd>
<dt><a name="footnote-16" href="#footnote-reference-16">11</a></dt>
<dd><p class="First">Efficacy for this organism in this organ system was studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p></dd>
<dt><a name="footnote-17" href="#footnote-reference-17">12</a></dt>
<dd><p class="First">Efficacy for this organism in this organ system was studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p></dd>
<dt><a name="footnote-18" href="#footnote-reference-18">13</a></dt>
<dd><p class="First">Efficacy for this organism in this organ system was studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p></dd>
<dt><a name="footnote-19" href="#footnote-reference-19">14</a></dt>
<dd><p class="First">Efficacy for this organism in this organ system was studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p></dd>
<dt><a name="footnote-20" href="#footnote-reference-20">15</a></dt>
<dd><p class="First">Efficacy for this organism in this organ system was studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p></dd>
<dt><a name="footnote-21" href="#footnote-reference-21">16</a></dt>
<dd><p class="First">Efficacy for this organism in this organ system was studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p></dd>
<dt><a name="footnote-22" href="#footnote-reference-22">17</a></dt>
<dd><p class="First">Efficacy for this organism in this organ system was studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p></dd>
<dt><a name="footnote-23" href="#footnote-reference-23">18</a></dt>
<dd><p class="First">Efficacy for this organism in this organ system was studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p></dd>
<dt><a name="footnote-24" href="#footnote-reference-24">19</a></dt>
<dd><p class="First">Efficacy for this organism in this organ system was studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p></dd>
</dl>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_b3ebf8f8-9120-4a23-bc84-02976c63930d"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">PRIMAXIN I.V. is contraindicated in patients who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any component of this product.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_d6dea7bf-5a76-46d6-8106-98de09cbc3a4"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">SERIOUS AND OCCASIONALLY FATAL <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY</span> (ANAPHYLACTIC) REACTIONS HAVE BEEN REPORTED IN PATIENTS RECEIVING THERAPY WITH BETA-LACTAMS. THESE REACTIONS ARE MORE APT TO OCCUR IN PERSONS WITH A HISTORY OF SENSITIVITY TO MULTIPLE ALLERGENS.</p>
<p>THERE HAVE BEEN REPORTS OF PATIENTS WITH A HISTORY OF PENICILLIN <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY</span> WHO HAVE EXPERIENCED SEVERE <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> WHEN TREATED WITH ANOTHER BETA-LACTAM. BEFORE INITIATING THERAPY WITH PRIMAXIN I.V., CAREFUL INQUIRY SHOULD BE MADE CONCERNING PREVIOUS <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> TO PENICILLINS, CEPHALOSPORINS, OTHER BETA‑LACTAMS, AND OTHER ALLERGENS. IF AN <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">ALLERGIC REACTION</span> OCCURS, PRIMAXIN SHOULD BE DISCONTINUED.</p>
<p><span class="Bold"><span class="Emphasis">SERIOUS <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">ANAPHYLACTIC REACTIONS</span> REQUIRE IMMEDIATE EMERGENCY TREATMENT WITH EPINEPHRINE. OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, MAY ALSO BE ADMINISTERED AS INDICATED. </span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1b3659ef-4e20-4ddd-998a-f41852e1730f"></a><a name="section-6.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> Potential</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> and other CNS adverse experiences, such as <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusional states</span> and myoclonic activity, have been reported during treatment with PRIMAXIN I.V. (See <a href="#i4i_precautions_id_75aee176-216e-4c21-bb09-50f48172d3da">PRECAUTIONS</a> and <a href="#i4i_adverse_effects_id_a1846735-cf68-4d0e-acd8-bb0396d805ad">ADVERSE REACTIONS</a>.)</p>
<p>Case reports in the literature have shown that co-administration of carbapenems, including imipenem, to patients receiving valproic acid or divalproex sodium results in a reduction in valproic acid concentrations. The valproic acid concentrations may drop below the therapeutic range as a result of this interaction, therefore increasing the risk of breakthrough <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. Increasing the dose of valproic acid or divalproex sodium may not be sufficient to overcome this interaction. The concomitant use of imipenem and valproic acid/divalproex sodium is generally not recommended. Anti-bacterials other than carbapenems should be considered to treat <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in patients whose <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> are well controlled on valproic acid or divalproex sodium. If administration of PRIMAXIN I.V. is necessary, supplemental anti-convulsant therapy should be considered (see <a href="#i4i_interactions_id_e0a3e9fd-f343-43f3-88f5-4075e180eee5">PRECAUTIONS, Drug Interactions</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6b9397b3-d926-4abb-8d1b-9c2e611d2614"></a><a name="section-6.2"></a><p></p>
<p class="First"><span class="Italics">Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including PRIMAXIN I.V., and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile</span>.</p>
<p><span class="Italics">C. difficile</span> produces toxins A and B which contribute to the development of CDAD. </p>
<p>Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile</span> cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics">C. difficile </span>may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics">C. difficile, </span>and surgical evaluation should be instituted as clinically indicated.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_75aee176-216e-4c21-bb09-50f48172d3da"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_c0cb2381-dba4-46eb-8238-99d484639a1b"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">CNS adverse experiences such as <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusional states</span>, myoclonic activity, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> have been reported during treatment with PRIMAXIN I.V., especially when recommended dosages were exceeded. These experiences have occurred most commonly in patients with CNS disorders (e.g., brain lesions or history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>) and/or compromised renal function. However, there have been reports of CNS adverse experiences in patients who had no recognized or documented underlying CNS disorder or compromised renal function.</p>
<p>When recommended doses were exceeded, adult patients with creatinine clearances of ≤20 mL/min/1.73 m<span class="Sup">2</span>, whether or not undergoing hemodialysis, had a higher risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> activity than those without impairment of renal function. Therefore, close adherence to the dosing guidelines for these patients is recommended. (See <a href="#i4i_dosage_admin_id_f8c49d4e-a947-4717-a237-be0dafc4f4d6">DOSAGE AND ADMINISTRATION</a>.)</p>
<p>Patients with creatinine clearances of ≤5 mL/min/1.73 m<span class="Sup">2</span> should not receive PRIMAXIN I.V. unless hemodialysis is instituted within 48 hours.</p>
<p>For patients on hemodialysis, PRIMAXIN I.V. is recommended only when the benefit outweighs the potential risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.</p>
<p>Close adherence to the recommended dosage and dosage schedules is urged, especially in patients with known factors that predispose to convulsive activity. Anticonvulsant therapy should be continued in patients with known <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorders. If focal <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of PRIMAXIN I.V. re-examined to determine whether it should be decreased or the antibiotic discontinued.</p>
<p>As with other antibiotics, prolonged use of PRIMAXIN I.V. may result in overgrowth of nonsusceptible organisms. Repeated evaluation of the patient's condition is essential. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs during therapy, appropriate measures should be taken.</p>
<p>Prescribing PRIMAXIN I.V. in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_432a4d36-2860-4ac9-8e0e-c6ee7aab2f3f"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be counseled to inform their physician if they are taking valproic acid or divalproex sodium. Valproic acid concentrations in the blood may drop below the therapeutic range upon co-administration with PRIMAXIN I.V. If treatment with PRIMAXIN I.V. is necessary and continued, alternative or supplemental anti-convulsant medication to prevent and/or treat <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> may be needed.</p>
<p>Patients should be counseled that antibacterial drugs including PRIMAXIN I.V. should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When PRIMAXIN I.V. is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by PRIMAXIN I.V. or other antibacterial drugs in the future.</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics, which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_5c441782-a2f5-430a-8361-7edcf622876a"></a><a name="section-7.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">While PRIMAXIN I.V. possesses the characteristic low toxicity of the beta-lactam group of antibiotics, periodic assessment of organ system functions, including renal, hepatic, and hematopoietic, is advisable during prolonged therapy.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_e0a3e9fd-f343-43f3-88f5-4075e180eee5"></a><a name="section-7.4"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Generalized <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> have been reported in patients who received ganciclovir and PRIMAXIN. These drugs should not be used concomitantly unless the potential benefits outweigh the risks.</p>
<p>Since concomitant administration of PRIMAXIN and probenecid results in only minimal increases in plasma levels of imipenem and plasma half-life, it is not recommended that probenecid be given with PRIMAXIN.</p>
<p>PRIMAXIN should not be mixed with or physically added to other antibiotics. However, PRIMAXIN may be administered concomitantly with other antibiotics, such as aminoglycosides.</p>
<p>Case reports in the literature have shown that co-administration of carbapenems, including imipenem, to patients receiving valproic acid or divalproex sodium results in a reduction in valproic acid concentrations. The valproic acid concentrations may drop below the therapeutic range as a result of this interaction, therefore increasing the risk of breakthrough <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. Although the mechanism of this interaction is unknown, data from <span class="Italics">in vitro</span> and animal studies suggest that carbapenems may inhibit the hydrolysis of valproic acid's glucuronide metabolite (VPA-g) back to valproic acid, thus decreasing the serum concentrations of valproic acid (see <a href="#i4i_section_id_1b3659ef-4e20-4ddd-998a-f41852e1730f">WARNINGS, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> Potential</a>).</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_d7fe966b-c802-41f1-93ef-86034bc122f2"></a><a name="section-7.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long term studies in animals have not been performed to evaluate carcinogenic potential of imipenem-cilastatin. Genetic toxicity studies were performed in a variety of bacterial and mammalian tests <span class="Italics">in vivo</span> and <span class="Italics">in vitro</span>. The tests used were: V79 mammalian cell mutagenesis assay (imipenem-cilastatin sodium alone and imipenem alone), Ames test (cilastatin sodium alone and imipenem alone), unscheduled DNA synthesis assay (imipenem-cilastatin sodium) and <span class="Italics">in vivo</span> mouse cytogenetics test (imipenem-cilastatin sodium). None of these tests showed any evidence of genetic alterations.</p>
<p>Reproductive tests in male and female rats were performed with imipenem-cilastatin sodium at intravenous doses up to 80 mg/kg/day and at a subcutaneous dose of 320 mg/kg/day, approximately equal to the highest recommended human dose of the intravenous formulation (on a mg/m<span class="Sup">2</span> body surface area basis). Slight decreases in live fetal body weight were restricted to the highest dosage level. No other adverse effects were observed on fertility, reproductive performance, fetal viability, growth or postnatal development of pups.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_3f2a6681-d295-43a5-8887-3c0513fe47b1"></a><a name="section-7.6"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_e15ca8c1-45f8-4b83-b7db-dd937773ca7e"></a><a name="section-7.6.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_de0253df-d5c8-4fa2-b4df-2685a72d9076"></a><a name="section-7.6.1.1"></a><p></p>
<h4>Pregnancy Category C:</h4>
<p class="First">Teratology studies with cilastatin sodium at doses of 30, 100, and 300 mg/kg/day administered intravenously to rabbits and 40, 200, and 1000 mg/kg/day administered subcutaneously to rats, up to approximately 1.9 and 3.2 times<a name="footnote-reference-25" href="#footnote-25" class="Sup">20</a> the maximum recommended daily human dose (on a mg/m<span class="Sup">2</span> body surface area basis) of the intravenous formulation of imipenem-cilastatin sodium (50 mg/kg/day) in the two species, respectively, showed no evidence of adverse effect on the fetus. No evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was observed in rabbits given imipenem at intravenous doses of 15, 30 or 60 mg/kg/day and rats given imipenem at intravenous doses of 225, 450, or 900 mg/kg/day, up to approximately 0.4 and 2.9 times<a name="footnote-reference-26" href="#footnote-26" class="Sup">21</a> the maximum recommended daily human dose (on a mg/m<span class="Sup">2</span> body surface area basis) in the two species, respectively.</p>
<p>Teratology studies with imipenem-cilastatin sodium at intravenous doses of 20 and 80, and a subcutaneous dose of 320 mg/kg/day, up to 0.5 times<a name="footnote-reference-27" href="#footnote-27" class="Sup">22</a> (mice) to approximately equal to (rats) the highest recommended daily intravenous human dose (on a mg/m<span class="Sup">2</span> body surface area basis) in pregnant rodents during the period of major organogenesis, revealed no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>.</p>
<p>Imipenem-cilastatin sodium, when administered subcutaneously to pregnant rabbits at dosages equivalent to the usual human dose of the intravenous formulation and higher (1000-4000 mg/day), caused body <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and maternal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>. When comparable doses of imipenem-cilastatin sodium were given to non-pregnant rabbits, body <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> were also observed. This intolerance is not unlike that seen with other beta‑lactam antibiotics in this species and is probably due to alteration of gut flora.</p>
<p>A teratology study in pregnant cynomolgus monkeys given imipenem-cilastatin sodium at doses of 40 mg/kg/day (bolus intravenous injection) or 160 mg/kg/day (subcutaneous injection) resulted in maternal toxicity including <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">inappetence</span>, body <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, abortion, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in some cases. In contrast, no significant toxicity was observed when non-pregnant cynomolgus monkeys were given doses of imipenem-cilastatin sodium up to 180 mg/kg/day (subcutaneous injection). When doses of imipenem-cilastatin sodium (approximately 100 mg/kg/day or approximately 0.6 times<a name="footnote-reference-28" href="#footnote-28" class="Sup">23</a> the maximum recommended daily human dose of the intravenous formulation) were administered to pregnant cynomolgus monkeys at an intravenous infusion rate which mimics human clinical use, there was minimal maternal intolerance (occasional <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>), no maternal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>, no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>, but an increase in embryonic loss relative to control groups.</p>
<p>No adverse effects on the fetus or on lactation were observed when imipenem-cilastatin sodium was administered subcutaneously to rats late in gestation at dosages up to 320 mg/kg/day, approximately equal to the highest recommended human dose (on a mg/m<span class="Sup">2</span> body surface area basis).</p>
<p>There are, however, no adequate and well-controlled studies in pregnant women. PRIMAXIN I.V. should be used during pregnancy only if the potential benefit justifies the potential risk to the mother and fetus.</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-25" href="#footnote-reference-25">20</a></dt>
<dd><p class="First">Based on patient body surface area of 1.6 m<span class="Sup">2</span> (weight of 60 kg).</p></dd>
<dt><a name="footnote-26" href="#footnote-reference-26">21</a></dt>
<dd><p class="First">Based on patient body surface area of 1.6 m<span class="Sup">2</span> (weight of 60 kg).</p></dd>
<dt><a name="footnote-27" href="#footnote-reference-27">22</a></dt>
<dd><p class="First">Based on patient body surface area of 1.6 m<span class="Sup">2</span> (weight of 60 kg).</p></dd>
<dt><a name="footnote-28" href="#footnote-reference-28">23</a></dt>
<dd><p class="First">Based on patient body surface area of 1.6 m<span class="Sup">2</span> (weight of 60 kg).</p></dd>
</dl>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_f4bf177a-7f7e-41fd-9054-c238fa0392c7"></a><a name="section-7.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether imipenem-cilastatin sodium is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when PRIMAXIN I.V. is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_49de5c25-49ec-4f5d-b1c3-d1d61c68c8fe"></a><a name="section-7.8"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Use of PRIMAXIN I.V. in pediatric patients, neonates to 16 years of age, is supported by evidence from adequate and well-controlled studies of PRIMAXIN I.V. in adults and by the following clinical studies and published literature in pediatric patients: Based on published studies of 178<a name="footnote-reference-29" href="#footnote-29" class="Sup">24</a> pediatric patients ≥3 months of age (with non-CNS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>), the recommended dose of PRIMAXIN I.V. is 15-25 mg/kg/dose administered every six hours. Doses of 25 mg/kg/dose in patients 3 months to &lt;3 years of age, and 15 mg/kg/dose in patients 3-12 years of age were associated with mean trough plasma concentrations of imipenem of 1.1±0.4 µg/mL and 0.6±0.2 µg/mL following multiple 60‑minute infusions, respectively; trough urinary concentrations of imipenem were in excess of 10 µg/mL for both doses. These doses have provided adequate plasma and urine concentrations for the treatment of non-CNS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Based on studies in adults, the maximum daily dose for treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> with fully susceptible organisms is 2.0 g per day, and of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> with moderately susceptible organisms (primarily some <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">P. aeruginosa</span>) is 4.0 g/day. (See <a href="#id_8dfb51aa-9093-44c6-868f-35c2b799db16">DOSAGE AND ADMINISTRATION, Table 3</a>.) Higher doses (up to 90 mg/kg/day in older children) have been used in patients with <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span>. (See <a href="#i4i_dosage_admin_id_f8c49d4e-a947-4717-a237-be0dafc4f4d6">DOSAGE AND ADMINISTRATION</a>.)</p>
<p>Based on studies of 135<a name="footnote-reference-30" href="#footnote-30" class="Sup">25</a> pediatric patients ≤3 months of age (weighing ≥1,500 g), the following dosage schedule is recommended for non-CNS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>:</p>
<p>&lt;1 wk of age: 25 mg/kg every 12 hrs</p>
<p>1-4 wks of age: 25 mg/kg every 8 hrs</p>
<p>4 wks-3 mos. of age: 25 mg/kg every 6 hrs.</p>
<p>In a published dose-ranging study of smaller premature infants (670-1,890 g) in the first week of life, a dose of 20 mg/kg q12h by 15-30 minutes infusion was associated with mean peak and trough plasma imipenem concentrations of 43 µg/mL and 1.7 µg/mL after multiple doses, respectively. However, moderate accumulation of cilastatin in neonates may occur following multiple doses of PRIMAXIN I.V. The safety of this accumulation is unknown.</p>
<p>PRIMAXIN I.V. is not recommended in pediatric patients with CNS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> because of the risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.</p>
<p>PRIMAXIN I.V. is not recommended in pediatric patients &lt;30 kg with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, as no data are available.</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-29" href="#footnote-reference-29">24</a></dt>
<dd><p class="First">Two patients were less than 3 months of age.</p></dd>
<dt><a name="footnote-30" href="#footnote-reference-30">25</a></dt>
<dd><p class="First">One patient was greater than 3 months of age.</p></dd>
</dl>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_2fd92d16-b6fa-4960-af94-e5a5d64ffcaa"></a><a name="section-7.9"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Of the approximately 3600 subjects ≥18 years of age in clinical studies of PRIMAXIN I.V., including postmarketing studies, approximately 2800 received PRIMAXIN I.V. Of the subjects who received PRIMAXIN I.V., data are available on approximately 800 subjects who were 65 and over, including approximately 300 subjects who were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</p>
<p>No dosage adjustment is required based on age (see <a href="#i4i_section_id_3ea1cf26-71b0-47e5-9c5d-cc4eb4c06b76">CLINICAL PHARMACOLOGY, Adults</a>). Dosage adjustment in the case of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is necessary (see <a href="#i4i_section_id_597f972a-3718-4be0-adbb-3f2d95c8b431">DOSAGE AND ADMINISTRATION, Reduced Intravenous Schedule for Adults with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span> and/or Body Weight &lt;70 kg</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_a1846735-cf68-4d0e-acd8-bb0396d805ad"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_460694f4-0734-400b-b3f6-c77187e753e5"></a><a name="section-8.1"></a><p></p>
<h2>Adults</h2>
<p class="First">PRIMAXIN I.V. is generally well tolerated. Many of the 1,723 patients treated in clinical trials were severely ill and had multiple background diseases and physiological impairments, making it difficult to determine causal relationship of adverse experiences to therapy with PRIMAXIN I.V.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_79989aa3-2ba3-464a-a977-3b3411ccbb8d"></a><a name="section-8.1.1"></a><p></p>
<h3>Local Adverse Reactions</h3>
<p class="First">Adverse local clinical reactions that were reported as possibly, probably, or definitely related to therapy with PRIMAXIN I.V. were:</p>
<p><span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">Phlebitis</span>/<span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span> — 3.1%</p>
<p><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> at the injection site — 0.7%</p>
<p><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span> at the injection site — 0.4%</p>
<p>Vein <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span> — 0.2%</p>
<p>Infused vein <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> — 0.1%</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b2ab9284-7ada-4267-8218-5561350f6282"></a><a name="section-8.1.2"></a><p></p>
<h3>Systemic Adverse Reactions</h3>
<p class="First">The most frequently reported systemic adverse clinical reactions that were reported as possibly, probably, or definitely related to PRIMAXIN I.V. were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (2.0%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (1.8%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (1.5%), <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (0.9%), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (0.5%), <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (0.4%), <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> (0.4%) (see <a href="#i4i_precautions_id_75aee176-216e-4c21-bb09-50f48172d3da">PRECAUTIONS</a>), <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (0.3%), <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (0.3%), <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> (0.2%), <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (0.2%).</p>
<p>Additional adverse systemic clinical reactions reported as possibly, probably, or definitely drug related occurring in less than 0.2% of the patients or reported since the drug was marketed are listed within each body system in order of decreasing severity: <span class="Italics">Gastrointestinal </span>— <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> (the onset of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> symptoms may occur during or after antibacterial treatment, see <a href="#i4i_warnings_id_d6dea7bf-5a76-46d6-8106-98de09cbc3a4">WARNINGS</a>), <span class="product-label-link" type="condition" conceptid="4216673" conceptname="Hemorrhagic colitis">hemorrhagic colitis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> (including fulminant <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>), <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, tongue papillar <span class="product-label-link" type="condition" conceptid="4210465" conceptname="Hypertrophy">hypertrophy</span>, staining of the teeth and/or tongue, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>, pharyngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">increased salivation</span>; <span class="Italics">Hematologic </span>— <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>; <span class="Italics">CNS </span>— <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="432586" conceptname="Mental disorder">psychic disturbances</span> including <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>; <span class="Italics">Special Senses </span>— <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>; <span class="Italics">Respiratory </span>— <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest discomfort</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span>, thoracic spine <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>; <span class="Italics">Cardiovascular </span>— <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>; <span class="Italics">Skin </span>— <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>, skin texture changes, <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candidiasis</span>, <span class="product-label-link" type="condition" conceptid="4194652" conceptname="Pruritus of vulva">pruritus vulvae</span>; <span class="Italics">Body as a whole </span>— <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">polyarthralgia</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>/<span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span>; <span class="Italics">Renal </span>— <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>/<span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="4055281" conceptname="Urine color abnormal">urine discoloration</span>. The role of PRIMAXIN I.V. in changes in renal function is difficult to assess, since factors predisposing to pre-renal <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span> or to <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> usually have been present.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0f95b7ca-7493-4c10-871e-a3edf0c8cfb2"></a><a name="section-8.1.3"></a><p></p>
<h3>Adverse Laboratory Changes</h3>
<p class="First">Adverse laboratory changes without regard to drug relationship that were reported during clinical trials or reported since the drug was marketed were:</p>
<p><span class="Italics">Hepatic:</span> Increased ALT (SGPT), AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>), alkaline phosphatase, bilirubin, and LDH</p>
<p><span class="Italics">Hemic:</span> Increased eosinophils, positive Coombs test, increased WBC, <span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">increased platelets</span>, <span class="product-label-link" type="condition" conceptid="4013074" conceptname="Hemoglobin low">decreased hemoglobin</span> and hematocrit, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, increased monocytes, abnormal <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, increased <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, increased <span class="product-label-link" type="condition" conceptid="4172647" conceptname="Basophil count">basophils</span></p>
<p><span class="Italics">Electrolytes:</span> Decreased serum sodium, increased potassium, increased chloride</p>
<p><span class="Italics">Renal:</span> Increased BUN, creatinine</p>
<p><span class="Italics">Urinalysis:</span> Presence of urine protein, urine red blood cells, urine white blood cells, urine casts, urine bilirubin, and urine urobilinogen.</p>
</div>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_3f844c3c-8d9f-43f7-9d80-af0208004ab7"></a><a name="section-8.2"></a><p></p>
<h2>Pediatric Patients</h2>
<p class="First">In studies of 178 pediatric patients ≥3 months of age, the following adverse events were noted:</p>
<a name="id_59a2a87d-bc97-4877-ae3a-e09387d489fe"></a><table>
<caption><span>The Most Common Clinical Adverse Experiences Without Regard to Drug Relationship (Patient Incidence &gt;1%)</span></caption>
<col align="left" width="50%">
<col align="center" width="50%">
<thead><tr class="First Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">Adverse Experience</td>
<td class="Botrule Rrule" align="center" valign="top">No. of Patients (%)</td>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-31" href="#footnote-reference-31">*</a></dt>
<dd>One patient had both <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and is counted in each category.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="Italics">Digestive System </span></td>
<td class="Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center" valign="top">7<a name="footnote-reference-31" href="#footnote-31" class="Sup">*</a> (3.9)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">Gastroenteritis</span></td>
<td class="Rrule" align="center" valign="top">2 (1.1)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center" valign="top">2<a href="#footnote-31" class="Sup">*</a> (1.1)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Italics">Skin</span></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Rrule" align="center" valign="top">4 (2.2)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">     Irritation, I.V. site</td>
<td class="Rrule" align="center" valign="top">2 (1.1)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Italics">Urogenital System </span></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4055281" conceptname="Urine color abnormal">Urine discoloration</span></td>
<td class="Rrule" align="center" valign="top">2 (1.1)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Italics">Cardiovascular System </span></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">Phlebitis</span></td>
<td class="Botrule Rrule" align="center" valign="top">4 (2.2)</td>
</tr>
</tbody>
</table>
<p>In studies of 135 patients (newborn to 3 months of age), the following adverse events were noted:</p>
<a name="id_fcfa116f-541d-41cc-8b62-d310d66a4fca"></a><table>
<caption><span>The Most Common Clinical Adverse Experiences Without Regard to Drug Relationship (Patient Incidence &gt;1%)</span></caption>
<col align="left" width="58%">
<col align="center" width="42%">
<thead><tr class="First Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">Adverse Experience</td>
<td class="Botrule Rrule" align="center" valign="top">No. of Patients (%)</td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="Italics">Digestive System </span></td>
<td class="Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center" valign="top">4 (3.0%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">Oral Candidiasis</span></td>
<td class="Rrule" align="center" valign="top">2 (1.5%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Italics">Skin</span></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Rrule" align="center" valign="top">2 (1.5%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Italics">Urogenital System </span></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">Oliguria</span>/<span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span></td>
<td class="Rrule" align="center" valign="top">3 (2.2%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Italics">Cardiovascular System </span></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span></td>
<td class="Rrule" align="center" valign="top">2 (1.5%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Italics">Nervous System</span></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span></td>
<td class="Botrule Rrule" align="center" valign="top">8 (5.9%)</td>
</tr>
</tbody>
</table>
<a name="id_2a3092e0-2caf-47ee-873b-e6f6acc86b36"></a><table>
<caption><span>Patients (≥3 Months of Age) With Normal Pretherapy but Abnormal During Therapy Laboratory Values</span></caption>
<col align="left" width="29%">
<col align="center" width="8%">
<col align="left" width="20%">
<col align="left" width="20%">
<col align="center" width="12%">
<col align="center" width="11%">
<thead><tr class="First Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">
<br>Laboratory Parameter</td>
<td class="Rrule" align="center" colspan="3" valign="top">
<br>Abnormality</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">
<br>No. of Patients With Abnormalities/No. of Patients With Lab Done<br>(%)</td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="top">Hemoglobin</td>
<td class="Toprule" align="left" valign="top">Age</td>
<td class="Toprule" align="left" valign="top">&lt;5 mos.:</td>
<td class="Rrule" align="left" valign="top">&lt;10 gm %<br>&lt;11.5 gm %</td>
<td class="Toprule" align="left" valign="top">19/129</td>
<td class="Rrule" align="left" valign="top">(14.7)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top">6 mos. – 12 yrs.:</td>
<td class="Rrule" align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Hematocrit</td>
<td align="left" valign="top">Age</td>
<td align="left" valign="top">&lt;5 mos.:</td>
<td class="Rrule" align="left" valign="top">&lt;30 vol %<br>&lt;34.5 vol %</td>
<td align="left" valign="top">23/129 </td>
<td class="Rrule" align="left" valign="top">(17.8)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top">6 mos. – 12 yrs.:</td>
<td class="Rrule" align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">Neutrophils</span></td>
<td class="Rrule" align="left" colspan="3" valign="top">                    ≤1000/mm<span class="Sup">3</span> (absolute)</td>
<td align="left" valign="top">4/123</td>
<td class="Rrule" align="left" valign="top">(3.3)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Eosinophils</td>
<td class="Rrule" align="left" colspan="3" valign="top">                    ≥7%</td>
<td align="left" valign="top">15/117</td>
<td class="Rrule" align="left" valign="top">(12.8)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Platelet Count</td>
<td class="Rrule" align="left" colspan="3" valign="top">                    ≥500 ths/mm<span class="Sup">3</span>
</td>
<td align="left" valign="top">16/119</td>
<td class="Rrule" align="left" valign="top">(13.4)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Urine Protein</td>
<td class="Rrule" align="left" colspan="3" valign="top">                    ≥1</td>
<td align="left" valign="top">8/97</td>
<td class="Rrule" align="left" valign="top">(8.2)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Serum Creatinine</td>
<td class="Rrule" align="left" colspan="3" valign="top">                    &gt;1.2 mg/dL</td>
<td align="left" valign="top">0/105</td>
<td class="Rrule" align="left" valign="top">(0)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">BUN</td>
<td class="Rrule" align="left" colspan="3" valign="top">                    &gt;22 mg/dL</td>
<td align="left" valign="top">0/108</td>
<td class="Rrule" align="left" valign="top">(0)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>)</td>
<td class="Rrule" align="left" colspan="3" valign="top">                    &gt;36 IU/L</td>
<td align="left" valign="top">14/78</td>
<td class="Rrule" align="left" valign="top">(17.9)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">ALT (SGPT)</td>
<td class="Rrule" align="left" colspan="3" valign="top">                    &gt;30 IU/L</td>
<td class="Botrule" align="left" valign="top">10/93</td>
<td class="Botrule Rrule" align="left" valign="top">(10.8)</td>
</tr>
</tbody>
</table>
<a name="id_01474efa-3111-4775-b654-50b2024eb2d2"></a><table>
<caption><span>Patients (&lt;3 Months of Age) With Normal Pretherapy but Abnormal During Therapy Laboratory Values</span></caption>
<col align="left" width="50%">
<col align="center" width="50%">
<thead><tr class="First Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">Laboratory Parameter</td>
<td class="Botrule Rrule" align="center" valign="top">No. of Patients With Abnormalities<a name="footnote-reference-32" href="#footnote-32" class="Sup">*</a> (%)</td>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-32" href="#footnote-reference-32">*</a></dt>
<dd>The denominator used for percentages was the number of patients for whom the test was performed during or post-treatment and, therefore, varies by test.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="top">Eosinophil Count↑</td>
<td class="Rrule" align="center" valign="top">11 (9.0%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Hematocrit↓</td>
<td class="Rrule" align="center" valign="top">3 (2.0%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Hematocrit↑</td>
<td class="Rrule" align="center" valign="top">1 (1.0%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Platelet Count↑</td>
<td class="Rrule" align="center" valign="top">5 (4.0%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Platelet Count↓</td>
<td class="Rrule" align="center" valign="top">2 (2.0%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Serum Creatinine↑</td>
<td class="Rrule" align="center" valign="top">5 (5.0%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Bilirubin↑</td>
<td class="Rrule" align="center" valign="top">3 (3.0%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Bilirubin↓</td>
<td class="Rrule" align="center" valign="top">1 (1.0%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>)↑</td>
<td class="Rrule" align="center" valign="top">5 (6.0%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">ALT (SGPT)↑</td>
<td class="Rrule" align="center" valign="top">3 (3.0%)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Serum Alkaline Phosphate↑</td>
<td class="Botrule Rrule" align="center" valign="top">2 (3.0%)</td>
</tr>
</tbody>
</table>
<p>Examination of published literature and spontaneous adverse event reports suggested a similar spectrum of adverse events in adult and pediatric patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_81188eee-d0e3-498f-8417-e70ee4ee0b4a"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">The acute intravenous toxicity of imipenem-cilastatin sodium in a ratio of 1:1 was studied in mice at doses of 751 to 1359 mg/kg. Following drug administration, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span> was rapidly produced and <span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic convulsions</span> were noted in about 45 minutes. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> occurred within 4-56 minutes at all doses.</p>
<p>The acute intravenous toxicity of imipenem-cilastatin sodium was produced within 5-10 minutes in rats at doses of 771 to 1583 mg/kg. In all dosage groups, females had <span class="product-label-link" type="condition" conceptid="4139968" conceptname="Underactive">decreased activity</span>, <span class="product-label-link" type="condition" conceptid="4314808" conceptname="Slow respiration">bradypnea</span>, and <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span> with <span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic convulsions</span> preceding <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>; in males, <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span> was seen at all dose levels while <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span> and <span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic convulsions</span> were seen at all but the lowest dose (771 mg/kg). In another rat study, female rats showed <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4314808" conceptname="Slow respiration">bradypnea</span>, and <span class="product-label-link" type="condition" conceptid="4139968" conceptname="Underactive">decreased activity</span> in all but the lowest dose (550 mg/kg); <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> were preceded by <span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic convulsions</span>. Male rats showed <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span> at all doses and <span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic convulsions</span> and <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span> were seen at the two highest doses (1130 and 1734 mg/kg). <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> occurred between 6 and 88 minutes with doses of 771 to 1734 mg/kg.</p>
<p>In the case of overdosage, discontinue PRIMAXIN I.V., treat symptomatically, and institute supportive measures as required. Imipenem-cilastatin sodium is hemodialyzable. However, usefulness of this procedure in the overdosage setting is questionable.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_f8c49d4e-a947-4717-a237-be0dafc4f4d6"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1919d622-bd33-4941-b1df-fe06e69edbdb"></a><a name="section-10.1"></a><p></p>
<h2>Adults</h2>
<p class="First">The dosage recommendations for PRIMAXIN I.V. represent the quantity of imipenem to be administered. An equivalent amount of cilastatin is also present in the solution. Each 125 mg, 250 mg, or 500 mg dose should be given by intravenous administration over 20 to 30 minutes. Each 750 mg or 1000 mg dose should be infused over 40 to 60 minutes. In patients who develop <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> during the infusion, the rate of infusion may be slowed.</p>
<p>The total daily dosage for PRIMAXIN I.V. should be based on the type or severity of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and given in equally divided doses based on consideration of degree of susceptibility of the pathogen(s), renal function, and body weight. Adult patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, as judged by creatinine clearance ≤70 mL/min/1.73 m<span class="Sup">2</span>, require adjustment of dosage as described in the succeeding section of these guidelines.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f02335d7-da29-4e6e-91e3-8c718b78915a"></a><a name="section-10.1.1"></a><p></p>
<h3>Intravenous Dosage Schedule for Adults with Normal Renal Function and Body Weight ≥70 kg</h3>
<p class="First">Doses cited in <a href="#id_8dfb51aa-9093-44c6-868f-35c2b799db16">Table 3</a> are based on a patient with normal renal function and a body weight of 70 kg. These doses should be used for a patient with a creatinine clearance of ≥71 mL/min/1.73 m<span class="Sup">2</span> and a body weight of ≥70 kg. A reduction in dose must be made for a patient with a creatinine clearance of ≤70 mL/min/1.73 m<span class="Sup">2</span> and/or a body weight less than 70 kg. (See <a href="#id_a0e9c047-3d31-4f13-b727-9af2ec43cc96">Tables 4</a> and <a href="#id_2924f0d8-e511-449c-bf66-8bb9f5800983">5</a>.)</p>
<p>Dosage regimens in column A of <a href="#id_8dfb51aa-9093-44c6-868f-35c2b799db16">Table 3</a> are recommended for <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by fully susceptible organisms which represent the majority of pathogenic species. Dosage regimens in column B of <a href="#id_8dfb51aa-9093-44c6-868f-35c2b799db16">Table 3</a> are recommended for <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by organisms with moderate susceptibility to imipenem, primarily some <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">P. aeruginosa</span>.</p>
<a name="id_8dfb51aa-9093-44c6-868f-35c2b799db16"></a><table>
<caption><span>TABLE 3: INTRAVENOUS DOSAGE SCHEDULE FOR ADULTS WITH NORMAL RENAL FUNCTION AND BODY WEIGHT ≥70 kg</span></caption>
<col align="left" width="25%">
<col align="center" width="40%">
<col align="center" width="35%">
<thead><tr class="First Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">
<br>Type or <br>Severity of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></td>
<td class="Rrule" align="center" valign="top">A<br>Fully susceptible organisms including gram-positive and gram-negative aerobes and anaerobes</td>
<td class="Botrule Rrule" align="center" valign="bottom">B<br>Moderately susceptible organisms, primarily some <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">P. aeruginosa</span>
</td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Mild</td>
<td class="Botrule Rrule" align="center" valign="top">250 mg q6h<br>(TOTAL DAILY DOSE = 1.0g)</td>
<td class="Botrule Rrule" align="center" valign="top">500 mg q6h<br>(TOTAL DAILY DOSE = 2.0g)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Moderate</td>
<td class="Botrule Rrule" align="center" valign="top">500 mg q8h<br>(TOTAL DAILY DOSE = 1.5g)<br>or<br>500 mg q6h<br>(TOTAL DAILY DOSE = 2.0g)</td>
<td class="Botrule Rrule" align="center" valign="top">500 mg q6h<br>(TOTAL DAILY DOSE = 2.0g)<br>or<br>1 g q8h<br>(TOTAL DAILY DOSE = 3.0g)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Severe, life<br>  threatening only</td>
<td class="Botrule Rrule" align="center" valign="top">500 mg q6h<br>(TOTAL DAILY DOSE = 2.0g)</td>
<td class="Botrule Rrule" align="center" valign="top">1 g q8h<br>(TOTAL DAILY DOSE = 3.0g)<br>or<br>1 g q6h<br>(TOTAL DAILY DOSE = 4.0g)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Uncomplicated<br>  <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span></td>
<td class="Botrule Rrule" align="center" valign="top">250 mg q6h<br>(TOTAL DAILY DOSE = 1.0g)</td>
<td class="Botrule Rrule" align="center" valign="top">250 mg q6h<br>(TOTAL DAILY DOSE = 1.0g)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Complicated<br>  <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span></td>
<td class="Rrule" align="center" valign="top">500 mg q6h<br>(TOTAL DAILY DOSE = 2.0g)</td>
<td class="Botrule Rrule" align="center" valign="top">500 mg q6h<br>(TOTAL DAILY DOSE = 2.0g)</td>
</tr>
</tbody>
</table>
<p><span class="Underline">Due to the high antimicrobial activity of PRIMAXIN I.V., it is recommended that the maximum total daily dosage not exceed 50 mg/kg/day or 4.0 g/day, whichever is lower</span>. There is no evidence that higher doses provide greater efficacy. However, patients over twelve years of age with <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> and normal renal function have been treated with PRIMAXIN I.V. at doses up to 90 mg/kg/day in divided doses, not exceeding 4.0 g/day.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_597f972a-3718-4be0-adbb-3f2d95c8b431"></a><a name="section-10.1.2"></a><p></p>
<h3>Reduced Intravenous Schedule for Adults with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span> and/or Body Weight &lt;70 kg</h3>
<p class="First">Patients with creatinine clearance of ≤70 mL/min/1.73 m<span class="Sup">2</span> and/or body weight less than 70 kg require dosage reduction of PRIMAXIN I.V. as indicated in the tables below. Creatinine clearance may be calculated from serum creatinine concentration by the following equation:</p>
<p>T<span class="Sub">cc</span> (Males)            =              <span class="Underline">(wt. in kg) (140 - age)</span><br>                                           (72) (creatinine in mg/dL)</p>
<p>T<span class="Sub">cc</span> (Females)        =             0.85 x (above value)</p>
<p>To determine the dose for adults with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> and/or reduced body weight:</p>
<ol>
<li>Choose a total daily dose from <a href="#id_8dfb51aa-9093-44c6-868f-35c2b799db16">Table 3</a> based on <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> characteristics.</li>
<li>a) If the total daily dose is 1.0 g, 1.5 g, or 2.0 g, use the appropriate subsection of <a href="#id_a0e9c047-3d31-4f13-b727-9af2ec43cc96">Table 4</a> and continue with step 3.<br>b) If the total daily dose is 3.0 g or 4.0 g, use the appropriate subsection of <a href="#id_2924f0d8-e511-449c-bf66-8bb9f5800983">Table 5</a> and continue with step 3.</li>
<li>From <a href="#id_a0e9c047-3d31-4f13-b727-9af2ec43cc96">Table 4</a> or <a href="#id_2924f0d8-e511-449c-bf66-8bb9f5800983">5</a>:<br>a) Select the body weight on the far left which is closest to the patient's body weight (kg).<br>b) Select the patient's creatinine clearance category.<br>c) Where the row and column intersect is the reduced dosage regimen.</li>
</ol>
<a name="id_a0e9c047-3d31-4f13-b727-9af2ec43cc96"></a><table>
<caption><span>TABLE 4: REDUCED INTRAVENOUS DOSAGE OF PRIMAXIN I.V. IN ADULT PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">IMPAIRED RENAL FUNCTION</span> AND/OR BODY WEIGHT &lt;70 kg</span></caption>
<col align="center" width="10%">
<col align="center" width="8%">
<col align="center" width="8%">
<col align="center" width="8%">
<col align="center" width="8%">
<col align="center" width="8%">
<col align="center" width="7%">
<col align="center" width="7%">
<col align="center" width="7%">
<col align="center" width="7%">
<col align="center" width="8%">
<col align="center" width="7%">
<col align="center" width="7%">
<thead>
<tr class="First">
<td class="Lrule Rrule Toprule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" colspan="12" valign="bottom">If TOTAL DAILY DOSE from TABLE 3 is:</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="bottom"></td>
<td class="Botrule Rrule" align="center" colspan="4" valign="bottom"> 1.0 g/day </td>
<td class="Botrule Rrule" align="center" colspan="4" valign="bottom"> 1.5 g/day </td>
<td class="Botrule Rrule" align="center" colspan="4" valign="bottom"> 2.0 g/day </td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="bottom">And Body Weight (kg) is: </td>
<td class="Rrule" align="center" colspan="4" valign="bottom">and creatinine clearance <br>(mL/min/1.73 m<span class="Sup">2</span>) is:</td>
<td class="Rrule" align="center" colspan="4" valign="bottom">and creatinine clearance <br>(mL/min/1.73 m<span class="Sup">2</span>) is:</td>
<td class="Rrule" align="center" colspan="4" valign="bottom">and creatinine clearance <br>(mL/min/1.73 m<span class="Sup">2</span>) is:</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top">≥71</td>
<td class="Botrule" align="center" valign="top">41-70</td>
<td class="Botrule" align="center" valign="top">21-40</td>
<td class="Rrule" align="center" valign="top">6-20</td>
<td class="Botrule" align="center" valign="top">≥71</td>
<td class="Botrule" align="center" valign="top">41-70</td>
<td class="Botrule" align="center" valign="top">21-40</td>
<td class="Rrule" align="center" valign="top">6-20</td>
<td class="Botrule" align="center" valign="top">≥71</td>
<td class="Botrule" align="center" valign="top">41-70</td>
<td class="Botrule" align="center" valign="top">21-40</td>
<td class="Botrule Rrule" align="center" valign="top">6-20</td>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Rrule" align="center" colspan="4" valign="bottom">then the reduced dosage regimen (mg) is:</td>
<td class="Rrule" align="center" colspan="4" valign="bottom">then the reduced dosage regimen (mg) is:</td>
<td class="Rrule" align="center" colspan="4" valign="bottom">then the reduced dosage regimen (mg) is:</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">≥70</td>
<td align="center" valign="top">250<br>q6h</td>
<td align="center" valign="top">250<br>q8h</td>
<td align="center" valign="top">250<br>q12h</td>
<td class="Rrule" align="center" valign="top">250<br>q12h</td>
<td align="center" valign="top">500<br>q8h</td>
<td align="center" valign="top">250<br>q6h</td>
<td align="center" valign="top">250<br>q8h</td>
<td class="Rrule" align="center" valign="top">250<br>q12h</td>
<td align="center" valign="top">500<br>q6h</td>
<td align="center" valign="top">500<br>q8h</td>
<td align="center" valign="top">250<br>q6h</td>
<td class="Rrule" align="center" valign="top">250<br>q12h</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">60</td>
<td align="center" valign="top">250<br>q8h</td>
<td align="center" valign="top">125<br>q6h</td>
<td align="center" valign="top">250<br>q12h</td>
<td class="Rrule" align="center" valign="top">125<br>q12h</td>
<td align="center" valign="top">250<br>q6h</td>
<td align="center" valign="top">250<br>q8h</td>
<td align="center" valign="top">250<br>q8h</td>
<td class="Rrule" align="center" valign="top">250<br>q12h</td>
<td align="center" valign="top">500<br>q8h</td>
<td align="center" valign="top">250<br>q6h</td>
<td align="center" valign="top">250<br>q8h</td>
<td class="Rrule" align="center" valign="top">250<br>q12h</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">50</td>
<td align="center" valign="top">125<br>q6h</td>
<td align="center" valign="top">125<br>q6h</td>
<td align="center" valign="top">125<br>q8h</td>
<td class="Rrule" align="center" valign="top">125<br>q12h</td>
<td align="center" valign="top">250<br>q6h</td>
<td align="center" valign="top">250<br>q8h</td>
<td align="center" valign="top">250<br>q12h</td>
<td class="Rrule" align="center" valign="top">250<br>q12h</td>
<td align="center" valign="top">250<br>q6h</td>
<td align="center" valign="top">250<br>q6h</td>
<td align="center" valign="top">250<br>q8h</td>
<td class="Rrule" align="center" valign="top">250<br>q12h</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">40</td>
<td align="center" valign="top">125<br>q6h</td>
<td align="center" valign="top">125<br>q8h</td>
<td align="center" valign="top">125<br>q12h</td>
<td class="Rrule" align="center" valign="top">125<br>q12h</td>
<td align="center" valign="top">250<br>q8h</td>
<td align="center" valign="top">125<br>q6h</td>
<td align="center" valign="top">125<br>q8h</td>
<td class="Rrule" align="center" valign="top">125<br>q12h</td>
<td align="center" valign="top">250<br>q6h</td>
<td align="center" valign="top">250<br>q8h</td>
<td align="center" valign="top">250<br>q12h</td>
<td class="Rrule" align="center" valign="top">250<br>q12h</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">30</td>
<td class="Botrule" align="center" valign="top">125<br>q8h</td>
<td class="Botrule" align="center" valign="top">125<br>q8h</td>
<td class="Botrule" align="center" valign="top">125<br>q12h</td>
<td class="Rrule" align="center" valign="top">125<br>q12h</td>
<td class="Botrule" align="center" valign="top">125<br>q6h</td>
<td class="Botrule" align="center" valign="top">125<br>q8h</td>
<td class="Botrule" align="center" valign="top">125<br>q8h</td>
<td class="Rrule" align="center" valign="top">125<br>q12h</td>
<td class="Botrule" align="center" valign="top">250<br>q8h</td>
<td class="Botrule" align="center" valign="top">125<br>q6h</td>
<td class="Botrule" align="center" valign="top">125<br>q8h</td>
<td class="Botrule Rrule" align="center" valign="top">125<br>q12h</td>
</tr>
</tbody>
</table>
<a name="id_2924f0d8-e511-449c-bf66-8bb9f5800983"></a><table>
<caption><span>TABLE 5: REDUCED INTRAVENOUS DOSAGE OF PRIMAXIN I.V. IN ADULT PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">IMPAIRED RENAL FUNCTION</span> AND/OR BODY WEIGHT &lt;70 kg</span></caption>
<col align="center" width="9%">
<col align="center" width="10%">
<col align="center" width="11%">
<col align="center" width="11%">
<col align="center" width="11%">
<col align="center" width="12%">
<col align="center" width="12%">
<col align="center" width="12%">
<col align="center" width="12%">
<thead>
<tr class="First"><td class="Lrule Rrule" align="center" colspan="9" valign="bottom">If TOTAL DAILY DOSE from TABLE 3 is:</td></tr>
<tr>
<td class="Lrule Rrule" align="center" valign="bottom"></td>
<td class="Botrule Rrule" align="center" colspan="4" valign="bottom"> 3.0 g/day </td>
<td class="Botrule Rrule" align="center" colspan="4" valign="bottom"> 4.0 g/day </td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="bottom">And Body Weight (kg) is:</td>
<td class="Rrule" align="center" colspan="4" valign="bottom">and creatinine clearance <br>(mL/min/1.73 m<span class="Sup">2</span>) is:</td>
<td class="Rrule" align="center" colspan="4" valign="bottom">and creatinine clearance <br>(mL/min/1.73 m<span class="Sup">2</span>) is:</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top">≥71</td>
<td class="Botrule" align="center" valign="top">41-70</td>
<td class="Botrule" align="center" valign="top">21-40</td>
<td class="Rrule" align="center" valign="top">6-20</td>
<td class="Botrule" align="center" valign="top">≥71</td>
<td class="Botrule" align="center" valign="top">41-70</td>
<td class="Botrule" align="center" valign="top">21-40</td>
<td class="Botrule Rrule" align="center" valign="top">6-20</td>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Rrule" align="center" colspan="4" valign="bottom">then the reduced dosage regimen (mg) is:</td>
<td class="Rrule" align="center" colspan="4" valign="bottom">then the reduced dosage regimen (mg) is:</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">≥70</td>
<td align="center" valign="top">1000<br>q8h</td>
<td align="center" valign="top">500<br>q6h</td>
<td align="center" valign="top">500<br>q8h</td>
<td class="Rrule" align="center" valign="top">500<br>q12h</td>
<td align="center" valign="top">1000<br>q6h</td>
<td align="center" valign="top">750<br>q8h</td>
<td align="center" valign="top">500<br>q6h</td>
<td class="Rrule" align="center" valign="top">500<br>q12h</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">60</td>
<td align="center" valign="top">750<br>q8h</td>
<td align="center" valign="top">500<br>q8h</td>
<td align="center" valign="top">500<br>q8h</td>
<td class="Rrule" align="center" valign="top">500<br>q12h</td>
<td align="center" valign="top">1000<br>q8h</td>
<td align="center" valign="top">750<br>q8h</td>
<td align="center" valign="top">500<br>q8h</td>
<td class="Rrule" align="center" valign="top">500<br>q12h</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">50</td>
<td align="center" valign="top">500<br>q6h</td>
<td align="center" valign="top">500<br>q8h</td>
<td align="center" valign="top">250<br>q6h</td>
<td class="Rrule" align="center" valign="top">250<br>q12h</td>
<td align="center" valign="top">750<br>q8h</td>
<td align="center" valign="top">500<br>q6h</td>
<td align="center" valign="top">500<br>q8h</td>
<td class="Rrule" align="center" valign="top">500<br>q12h</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">40</td>
<td align="center" valign="top">500<br>q8h</td>
<td align="center" valign="top">250<br>q6h</td>
<td align="center" valign="top">250<br>q8h</td>
<td class="Rrule" align="center" valign="top">250<br>q12h</td>
<td align="center" valign="top">500<br>q6h</td>
<td align="center" valign="top">500<br>q8h</td>
<td align="center" valign="top">250<br>q6h</td>
<td class="Rrule" align="center" valign="top">250<br>q12h</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">30</td>
<td class="Botrule" align="center" valign="top">250<br>q6h</td>
<td class="Botrule" align="center" valign="top">250<br>q8h</td>
<td class="Botrule" align="center" valign="top">250<br>q8h</td>
<td class="Rrule" align="center" valign="top">250<br>q12h</td>
<td class="Botrule" align="center" valign="top">500<br>q8h</td>
<td class="Botrule" align="center" valign="top">250<br>q6h</td>
<td class="Botrule" align="center" valign="top">250<br>q8h</td>
<td class="Botrule Rrule" align="center" valign="top">250<br>q12h</td>
</tr>
</tbody>
</table>
<p>Patients with <span class="Underline">creatinine clearances of 6 to 20 mL/min/1.73 m<span class="Sup">2</span></span> should be treated with PRIMAXIN I.V. 125 mg or 250 mg every 12 hours for most pathogens. There may be an increased risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> when doses of 500 mg every 12 hours are administered to these patients.</p>
<p>Patients with creatinine clearance ≤5 mL/min/1.73 m<span class="Sup">2</span> should not receive PRIMAXIN I.V. unless hemodialysis is instituted within 48 hours. There is inadequate information to recommend usage of PRIMAXIN I.V. for patients undergoing peritoneal dialysis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_909388a4-de1e-49e2-976d-37d69d917814"></a><a name="section-10.1.3"></a><p></p>
<h3>Hemodialysis</h3>
<p class="First">When treating patients with <span class="Underline">creatinine clearances of ≤5 mL/min/1.73 m<span class="Sup">2</span> who are undergoing hemodialysis</span>, use the dosage recommendations for patients with creatinine clearances of 6-20 mL/min/1.73 m<span class="Sup">2</span>. (See <a href="#i4i_section_id_597f972a-3718-4be0-adbb-3f2d95c8b431">Reduced Intravenous Dosage Schedule for Adults with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span> and/or Body Weight &lt;70 kg</a>.) Both imipenem and cilastatin are cleared from the circulation during hemodialysis. The patient should receive PRIMAXIN I.V. after hemodialysis and at 12 hour intervals timed from the end of that hemodialysis session. Dialysis patients, especially those with background CNS disease, should be carefully monitored; for patients on hemodialysis, PRIMAXIN I.V. is recommended only when the benefit outweighs the potential risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. (See <a href="#i4i_precautions_id_75aee176-216e-4c21-bb09-50f48172d3da">PRECAUTIONS</a>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_f69fa430-15e5-43e2-a246-c8493af1a05d"></a><a name="section-10.2"></a><p></p>
<h2>Pediatric Patients</h2>
<p class="First">See <a href="#i4i_pediatric_use_id_49de5c25-49ec-4f5d-b1c3-d1d61c68c8fe">PRECAUTIONS, Pediatric Patients</a>.</p>
<p>For pediatric patients ≥3 months of age, the recommended dose for non-CNS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> is 15-25 mg/kg/dose administered every six hours. Based on studies in adults, the maximum daily dose for treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> with fully susceptible organisms is 2.0 g per day, and of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> with moderately susceptible organisms (primarily some <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">P. aeruginosa</span>) is 4.0 g/day. Higher doses (up to 90 mg/kg/day in older children) have been used in patients with <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span>.</p>
<p>For pediatric patients ≤3 months of age (weighing ≥1,500 g), the following dosage schedule is recommended for non-CNS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>:</p>
<p>&lt;1 wk of age: 25 mg/kg every 12 hrs</p>
<p>1-4 wks of age: 25 mg/kg every 8 hrs</p>
<p>4 wks-3 mos. of age: 25 mg/kg every 6 hrs.</p>
<p>Doses less than or equal to 500 mg should be given by intravenous infusion over 15 to 30 minutes. Doses greater than 500 mg should be given by intravenous infusion over 40 to 60 minutes.</p>
<p>PRIMAXIN I.V. is not recommended in pediatric patients with CNS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> because of the risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.</p>
<p>PRIMAXIN I.V. is not recommended in pediatric patients &lt;30 kg with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, as no data are available.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e5566b32-1d3e-489f-b5cf-cfb01c279bdb"></a><a name="section-11"></a><p></p>
<h1>PREPARATION OF SOLUTION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_be873b27-a852-4c7f-bae9-c75918e39ed3"></a><a name="section-11.1"></a><p></p>
<h2>Vials</h2>
<p class="First">Contents of the vials must be suspended and transferred to 100 mL of an appropriate infusion solution. </p>
<p>A suggested procedure is to add approximately 10 mL from the appropriate infusion solution (see list of diluents under <a href="#i4i_section_id_fdfde20b-980f-4ddc-9dee-f792773c4c40">COMPATIBILITY AND STABILITY</a>) to the vial. Shake well and transfer the resulting suspension to the infusion solution container.</p>
<p><span class="Bold"><span class="Emphasis">Benzyl alcohol as a preservative has been associated with toxicity in neonates. While toxicity has not been demonstrated in pediatric patients greater than three months of age, small pediatric patients in this age range may also be at risk for benzyl alcohol toxicity. Therefore, diluents containing benzyl alcohol should not be used when PRIMAXIN I.V. is constituted for administration to pediatric patients in this age range.</span></span></p>
<p>CAUTION: THE SUSPENSION IS NOT FOR DIRECT INFUSION.</p>
<p>Repeat with an additional 10 mL of infusion solution to ensure complete transfer of vial contents to the infusion solution. <span class="Bold"><span class="Emphasis">The resulting mixture should be <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> until clear.</span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a21f90be-8c66-4a9a-97e2-0c750e5d4b33"></a><a name="section-11.2"></a><p></p>
<p class="First"><span class="Bold">ADD-Vantage<span class="Sup">®</span><a name="footnote-reference-33" href="#footnote-33" class="Sup">26</a> Vials</span><br></p>
<p>See separate <a href="#i4i_section_id_453c42c7-d8af-4be0-bc4b-cc182be13a0b">INSTRUCTIONS FOR USE OF 'PRIMAXIN I.V.' IN ADD-Vantage® VIALS</a>. PRIMAXIN I.V. in ADD‑Vantage<span class="Sup">®</span> vials should be reconstituted with ADD‑Vantage<span class="Sup">®</span> diluent containers containing 100 mL of either 0.9% Sodium Chloride Injection or 100 mL 5% Dextrose Injection.</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-33" href="#footnote-reference-33">26</a></dt>
<dd><p class="First">Registered trademark of Abbott Laboratories, Inc.</p></dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fdfde20b-980f-4ddc-9dee-f792773c4c40"></a><a name="section-12"></a><p></p>
<h1>COMPATIBILITY AND STABILITY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5ff56ec0-d026-442a-a103-252a3ecb28fa"></a><a name="section-12.1"></a><p></p>
<h2>Before Reconstitution:</h2>
<p class="First">The dry powder should be stored at a temperature below 25°C (77°F).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a82726cc-4902-4b11-ad3d-93c5b94ff2a4"></a><a name="section-12.2"></a><p></p>
<h2>Reconstituted Solutions:</h2>
<p class="First">Solutions of PRIMAXIN I.V. range from colorless to yellow. Variations of color within this range do not affect the potency of the product.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_931a15f9-889e-4adb-87ca-1000bbbb96da"></a><a name="section-12.3"></a><p></p>
<h2>Vials</h2>
<p class="First">PRIMAXIN I.V., as supplied in single use vials and reconstituted with the following diluents (see <a href="#i4i_section_id_e5566b32-1d3e-489f-b5cf-cfb01c279bdb">PREPARATION OF SOLUTION</a>), maintains satisfactory potency for 4 hours at room temperature or for 24 hours under refrigeration (5°C). Solutions of PRIMAXIN I.V. should not be frozen.</p>
<p>0.9% Sodium Chloride Injection</p>
<p>5% or 10% Dextrose Injection</p>
<p>5% Dextrose and 0.9% Sodium Chloride Injection</p>
<p>5% Dextrose Injection with 0.225% or 0.45% saline solution</p>
<p>5% Dextrose Injection with 0.15% potassium chloride solution</p>
<p>Mannitol 5% and 10%</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_22b58ea1-8e62-4fa2-9abc-8aedf75bd915"></a><a name="section-12.4"></a><p></p>
<h2>ADD-Vantage<span class="Sup">®</span> vials</h2>
<p class="First">PRIMAXIN I.V., as supplied in single dose ADD‑Vantage<span class="Sup">®</span> vials and reconstituted with the following diluents (see <a href="#i4i_section_id_e5566b32-1d3e-489f-b5cf-cfb01c279bdb">PREPARATION OF SOLUTION</a>), maintains satisfactory potency for 4 hours at room temperature.</p>
<p>0.9% Sodium Chloride Injection</p>
<p>5% Dextrose Injection</p>
<p>PRIMAXIN I.V. should not be mixed with or physically added to other antibiotics. However, PRIMAXIN I.V. may be administered concomitantly with other antibiotics, such as aminoglycosides.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_c4aca2a4-d990-44dd-bf3e-b55ef473934e"></a><a name="section-13"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">PRIMAXIN I.V. is supplied as a sterile powder mixture in single dose containers including vials and ADD-Vantage<span class="Sup">®</span> vials containing imipenem (anhydrous equivalent) and cilastatin sodium as follows:</p>
<p>No. 3514 — 250 mg imipenem equivalent and 250 mg cilastatin equivalent and 10 mg sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> as a buffer</p>
<p><span class="Bold"><span class="Emphasis">NDC</span></span> 0006-3514-58 in trays of 25 vials.</p>
<p>No. 3516 — 500 mg imipenem equivalent and 500 mg cilastatin equivalent and 20 mg sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> as a buffer</p>
<p><span class="Bold"><span class="Emphasis">NDC</span></span> 0006-3516-59 in trays of 25 vials.</p>
<p>No. 3551 — 250 mg imipenem equivalent and 250 mg cilastatin equivalent and 10 mg sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> as a buffer</p>
<p><span class="Bold"><span class="Emphasis">NDC</span></span> 0006-3551-58 in trays of 25 ADD‑Vantage<span class="Sup">®</span> vials.</p>
<p>No. 3552 — 500 mg imipenem equivalent and 500 mg cilastatin equivalent and 20 mg sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> as a buffer</p>
<p><span class="Bold"><span class="Emphasis">NDC</span></span> 0006-3552-59 in trays of 25 ADD‑Vantage<span class="Sup">®</span> vials.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_577a9b2c-a7ea-4cac-a4ce-65bd90e5715e"></a><a name="section-14"></a><p></p>
<h1>REFERENCES</h1>
<ol>
<li>Clinical and Laboratory Standards Institute (CLSI). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard - 9<span class="Sup">th</span> ed. CLSI document M07-A9. CLSI, 950 West Valley Rd., Suite 2500, Wayne, PA 19087, 2012.</li>
<li>CLSI. Performance Standards for Antimicrobial Susceptibility Testing; 22<span class="Sup">nd</span> Informational Supplement. CLSI document M100-S22, 2012.</li>
<li>CLSI. Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard – 11<span class="Sup">th</span> ed. CLSI document M02-A11, 2012.</li>
<li>CLSI. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard – 8<span class="Sup">th</span> ed. CLSI document M11-A8, 2012.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4bf36138-c9ec-4958-afae-d438d65842f8"></a><a name="section-15"></a><p></p>
<p class="First">Merck Sharp &amp; Dohme Corp., a subsidiary of<br><span class="Bold">MERCK &amp; CO., INC.,</span> Whitehouse Station, NJ 08889, USA</p>
<p>Copyright © 1987, 1994, 1998 Merck Sharp &amp; Dohme Corp., a subsidiary of <span class="Bold">Merck &amp; Co., Inc.</span><br>All rights reserved.</p>
<p>Revised: April 2012</p>
<p>USPI-IV-0787B1204R037</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_453c42c7-d8af-4be0-bc4b-cc182be13a0b"></a><a name="section-16"></a><p></p>
<h1>INSTRUCTIONS FOR USE OF PRIMAXIN<span class="Sup">®</span> I.V.</h1>
<p class="First"><span class="Bold"><span class="Emphasis">(Imipenem and Cilastatin for Injection) <br>(Formerly called Imipenem-Cilastatin Sodium for Injection) <br>IN ADD-Vantage<span class="Sup">®</span><a name="footnote-reference-34" href="#footnote-34" class="Sup">27</a> VIALS</span></span><br><br><span class="Bold"><span class="Emphasis">For IV Use Only. </span></span><br></p>
<p><span class="Italics">INSTRUCTIONS FOR USE</span></p>
<p><span class="Italics">To Open Diluent Container:</span></p>
<p> Peel overwrap from the corner and remove container. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. </p>
<p><span class="Italics">To Assemble Vial and Flexible Diluent Container: </span></p>
<p>(Use Aseptic Technique)</p>
<ol>
<li>Remove the protective covers from the top of the vial and the vial port on the diluent container as follows: <ol>
<li>To remove the breakaway vial cap, swing the pull ring over the top of the vial and pull down far enough to start the opening. (SEE FIGURE 1.) Pull the ring approximately half way around the cap and then pull straight up to remove the cap. (SEE FIGURE 2.) NOTE: DO NOT ACCESS VIAL WITH SYRINGE.<div class="Figure"><img alt="Figure 1 and Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7aa0ce90-156c-4583-ae6d-9ed3595960c8&amp;name=ebcb1bef-463a-4503-b847-68d45d0aced6-03.jpg"></div>
</li>
<li>To remove the vial port cover, grasp the tab on the pull ring, pull up to break the three tie strings, then pull back to remove the cover. (SEE FIGURE 3.)</li>
</ol>
</li>
<li>Screw the vial into the vial port until it will go no further. THE VIAL MUST BE SCREWED IN TIGHTLY TO ASSURE A SEAL. This occurs approximately ½ turn (180°) after the first audible click. (SEE FIGURE 4.) The clicking sound does not assure a seal; the vial must be turned as far as it will go. NOTE: Once vial is seated, do not attempt to remove. (SEE FIGURE 4.)</li>
<li>Recheck the vial to assure that it is tight by trying to turn it further in the direction of assembly.</li>
<li>Label appropriately.<div class="Figure"><img alt="Figure 3 and Figure 4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7aa0ce90-156c-4583-ae6d-9ed3595960c8&amp;name=ebcb1bef-463a-4503-b847-68d45d0aced6-04.jpg"></div>
</li>
</ol>
<p><span class="Italics">To Prepare Admixture: </span></p>
<ol>
<li>Squeeze the bottom of the diluent container gently to inflate the portion of the container surrounding the end of the drug vial. </li>
<li>With the other hand, push the drug vial down into the container telescoping the walls of the container. Grasp the inner cap of the vial through the walls of the container. (SEE FIGURE 5.) </li>
<li>Pull the inner cap from the drug vial. (SEE FIGURE 6.) Verify that the rubber stopper has been pulled out, allowing the drug and diluent to mix. </li>
<li>Mix container contents thoroughly and use within the specified time.<div class="Figure"><img alt="Figure 5 and Figure 6" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7aa0ce90-156c-4583-ae6d-9ed3595960c8&amp;name=ebcb1bef-463a-4503-b847-68d45d0aced6-05.jpg"></div>
</li>
</ol>
<p><span class="Italics"> Preparation for Administration:</span></p>
<p> (Use Aseptic Technique)</p>
<ol>
<li>Confirm the activation and admixture of vial contents.</li>
<li>Check for leaks by squeezing container firmly. If leaks are found, discard unit as <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> may be impaired.</li>
<li>Close flow control clamp of administration set.</li>
<li>Remove cover from outlet port at bottom of container.</li>
<li>Insert piercing pin of administration set into port with a twisting motion until the pin is firmly seated. NOTE: See full directions on administration set carton. </li>
<li>Lift the free end of the hanger loop on the bottom of the vial, breaking the two tie strings. Bend the loop outward to lock it in the upright position, then suspend container from hanger.</li>
<li>Squeeze and release drip chamber to establish proper fluid level in chamber.</li>
<li>Open flow control clamp and clear air from set. Close clamp.</li>
<li>Attach set to venipuncture device. If device is not indwelling, prime and make venipuncture.</li>
<li>Regulate rate of administration with flow control clamp.</li>
</ol>
<p><span class="Bold"><span class="Emphasis">WARNING: Do not use flexible container in series connections.</span></span></p>
<p><span class="Italics">Stability</span></p>
<p>PRIMAXIN I.V.<a name="footnote-reference-35" href="#footnote-35" class="Sup">28</a> (Imipenem and Cilastatin for Injection) 250 or 500 single dose ADD-Vantage<span class="Sup">®</span> vials should be prepared with ADD-Vantage<span class="Sup">®</span> diluent containers containing 100 mL of either 0.9 percent Sodium Chloride Injection or 5 percent Dextrose Injection. When prepared with either of these diluents, PRIMAXIN I.V. (Imipenem and Cilastatin for Injection) maintains satisfactory potency for 4 hours at room temperature.</p>
<p>Before administering, see accompanying package circular for PRIMAXIN I.V. (Imipenem and Cilastatin for Injection).</p>
<p>Issued February 2010</p>
<p>Printed In USA</p>
<p>9805601</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-34" href="#footnote-reference-34">27</a></dt>
<dd><p class="First">Registered trademark of Abbott Laboratories, Inc.</p></dd>
<dt><a name="footnote-35" href="#footnote-reference-35">28</a></dt>
<dd><p class="First">Registered trademark of Merck Sharp &amp; Dohme Corp., a subsidiary of <span class="Bold">Merck &amp; Co., Inc.</span></p></dd>
</dl>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_e6f436fa-e72a-46af-be37-e34cdf95543f"></a><a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 500 mg Bag</h1>
<p class="First">Primaxin<span class="Sup">®</span> I.V. 500</p>
<p>Imipenem and Cilastatin for Injection</p>
<p>500 mg</p>
<p>5 Add-Vantage<span class="Sup">®</span> Vials</p>
<div class="Figure"><img alt="bag label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7aa0ce90-156c-4583-ae6d-9ed3595960c8&amp;name=ebcb1bef-463a-4503-b847-68d45d0aced6-06.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_0f7f72ec-948d-4a34-bb6e-64070b8ed4e2"></a><a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 500 mg Bag</h1>
<p class="First">Primaxin<span class="Sup">®</span> I.V. 500</p>
<p>Imipenem and Cilastatin for Injection</p>
<p>500 mg</p>
<p>5 Vials</p>
<div class="Figure"><img alt="Bag Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7aa0ce90-156c-4583-ae6d-9ed3595960c8&amp;name=ebcb1bef-463a-4503-b847-68d45d0aced6-07.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PRIMAXIN 		
					IV</strong><br><span class="contentTableReg">imipenem and cilastatin sodium injection, powder, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55154-5030(NDC:0006-3516)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>IMIPENEM</strong> (IMIPENEM ANHYDROUS) </td>
<td class="formItem">IMIPENEM ANHYDROUS</td>
<td class="formItem">500 mg  in 100 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>CILASTATIN SODIUM</strong> (CILASTATIN) </td>
<td class="formItem">CILASTATIN</td>
<td class="formItem">500 mg  in 100 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">BICARBONATE</span></strong></td>
<td class="formItem">20 mg  in 100 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (colorless to yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55154-5030-5</td>
<td class="formItem">5  in 1 BAG</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">100 mL in 1 VIAL, SINGLE-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050587</td>
<td class="formItem">11/26/1985</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PRIMAXIN 		
					IV</strong><br><span class="contentTableReg">imipenem and cilastatin sodium injection, powder, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55154-5019(NDC:0006-3552)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>IMIPENEM</strong> (IMIPENEM ANHYDROUS) </td>
<td class="formItem">IMIPENEM ANHYDROUS</td>
<td class="formItem">500 mg  in 100 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>CILASTATIN SODIUM</strong> (CILASTATIN) </td>
<td class="formItem">CILASTATIN</td>
<td class="formItem">500 mg  in 100 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">BICARBONATE</span></strong></td>
<td class="formItem">20 mg  in 100 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (colorless to yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55154-5019-5</td>
<td class="formItem">5  in 1 BAG</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">100 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA062756</td>
<td class="formItem">01/08/1987</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Cardinal Health
							(188557102)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Cardinal Health</td>
<td class="formItem"></td>
<td class="formItem">188557102</td>
<td class="formItem">REPACK(55154-5030, 55154-5019)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>ebcb1bef-463a-4503-b847-68d45d0aced6</div>
<div>Set id: 7aa0ce90-156c-4583-ae6d-9ed3595960c8</div>
<div>Version: 3</div>
<div>Effective Time: 20130411</div>
</div>
</div> <div class="DistributorName">Cardinal Health</div></p>
</body></html>
